

# Antonio Torres

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5100417/publications.pdf>

Version: 2024-02-01

837  
papers

56,566  
citations

1294

109  
h-index

1745

212  
g-index

881  
all docs

881  
docs citations

881  
times ranked

33148  
citing authors

#	ARTICLE	IF	CITATIONS
1	Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults. <i>Clinical Infectious Diseases</i> , 2007, 44, S27-S72.	2.9	5,203
2	Guidelines for the Management of Adults with Community-acquired Pneumonia. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2001, 163, 1730-1754.	2.5	2,041
3	Supine body position as a risk factor for nosocomial pneumonia in mechanically ventilated patients: a randomised trial. <i>Lancet, The</i> , 1999, 354, 1851-1858.	6.3	1,254
4	Medical Section of the American Lung Association: Guidelines for the Initial Management of Adults with Community-acquired Pneumonia: Diagnosis, Assessment of Severity, and Initial Antimicrobial Therapy. <i>The American Review of Respiratory Disease</i> , 1993, 148, 1418-1426.	2.9	1,081
5	Incidence, Risk, and Prognosis Factors of Nosocomial Pneumonia in Mechanically Ventilated Patients. <i>The American Review of Respiratory Disease</i> , 1990, 142, 523-528.	2.9	874
6	Severe Community-acquired Pneumonia. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1998, 158, 1102-1108.	2.5	853
7	International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia. <i>European Respiratory Journal</i> , 2017, 50, 1700582.	3.1	792
8	European Respiratory Society guidelines for the management of adult bronchiectasis. <i>European Respiratory Journal</i> , 2017, 50, 1700629.	3.1	788
9	Non-invasive ventilation in community-acquired pneumonia and severe acute respiratory failure. <i>Intensive Care Medicine</i> , 2012, 38, 458-466.	3.9	756
10	Significance of the Isolation of <i>Candida</i> Species from Respiratory Samples in Critically Ill, Non-neutropenic Patients. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1997, 156, 583-590.	2.5	717
11	Nosocomial Pneumonia. <i>Chest</i> , 1988, 93, 318-324.	0.4	680
12	Effect of Spontaneous Breathing Trial Duration on Outcome of Attempts to Discontinue Mechanical Ventilation. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1999, 159, 512-518.	2.5	653
13	Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study. <i>Clinical Microbiology and Infection</i> , 2021, 27, 83-88.	2.8	636
14	Pulmonary Aspiration of Gastric Contents in Patients Receiving Mechanical Ventilation: The Effect of Body Position. <i>Annals of Internal Medicine</i> , 1992, 116, 540-543.	2.0	604
15	Bacterial Colonization Patterns in Mechanically Ventilated Patients with Traumatic and Medical Head Injury. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1999, 159, 188-198.	2.5	583
16	Noninvasive Ventilation in Severe Hypoxemic Respiratory Failure. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2003, 168, 1438-1444.	2.5	574
17	Etiology of Community-Acquired Pneumonia. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1999, 160, 397-405.	2.5	570
18	Severe Community-acquired Pneumonia: Epidemiology and Prognostic Factors. <i>The American Review of Respiratory Disease</i> , 1991, 144, 312-318.	2.9	564

#	ARTICLE	IF	CITATIONS
19	Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data. <i>Lancet Respiratory Medicine</i> , 2014, 2, 395-404.	5.2	527
20	Early Noninvasive Ventilation Averts Extubation Failure in Patients at Risk. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2006, 173, 164-170.	2.5	509
21	Risk factors for community-acquired pneumonia in adults in Europe: a literature review. <i>Thorax</i> , 2013, 68, 1057-1065.	2.7	489
22	Bronchial Microbial Patterns in Severe Exacerbations of Chronic Obstructive Pulmonary Disease (COPD) Requiring Mechanical Ventilation. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1998, 157, 1498-1505.	2.5	430
23	Effect of Corticosteroids on Treatment Failure Among Hospitalized Patients With Severe Community-Acquired Pneumonia and High Inflammatory Response. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 677.	3.8	428
24	Clinical diagnosis of ventilator associated pneumonia revisited: comparative validation using immediate post-mortem lung biopsies. <i>Thorax</i> , 1999, 54, 867-873.	2.7	416
25	Hemodynamic monitoring in shock and implications for management. <i>Intensive Care Medicine</i> , 2007, 33, 575-590.	3.9	407
26	Defining, treating and preventing hospital acquired pneumonia: European perspective. <i>Intensive Care Medicine</i> , 2009, 35, 9-29.	3.9	397
27	Community-acquired pneumonia. <i>Lancet, The</i> , 2015, 386, 1097-1108.	6.3	392
28	Noninvasive Ventilation during Persistent Weaning Failure. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2003, 168, 70-76.	2.5	375
29	The COVID-19 puzzle: deciphering pathophysiology and phenotypes of a new disease entity. <i>Lancet Respiratory Medicine</i> , 2021, 9, 622-642.	5.2	371
30	Addition of a Macrolide to a Î²-Lactam-Based Empirical Antibiotic Regimen Is Associated with Lower In-Hospital Mortality for Patients with Bacteremic Pneumococcal Pneumonia. <i>Clinical Infectious Diseases</i> , 2003, 36, 389-395.	2.9	355
31	Severe Community-acquired Pneumonia. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1999, 160, 923-929.	2.5	348
32	Community-Acquired Pneumonia Due to Gram-Negative Bacteria and <i>Pseudomonas aeruginosa</i> . <i>Archives of Internal Medicine</i> , 2002, 162, 1849.	4.3	335
33	Effects of internet-based training on antibiotic prescribing rates for acute respiratory-tract infections: a multinational, cluster, randomised, factorial, controlled trial. <i>Lancet, The</i> , 2013, 382, 1175-1182.	6.3	329
34	Noninvasive Versus Invasive Microbial Investigation in Ventilator-associated Pneumonia. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2000, 162, 119-125.	2.5	320
35	Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial. <i>Lancet Infectious Diseases</i> , 2018, 18, 285-295.	4.6	300
36	Epigenetic Silencing of the Tumor Suppressor MicroRNA<i>Hsa-miR-124a</i> Regulates CDK6 Expression and Confers a Poor Prognosis in Acute Lymphoblastic Leukemia. <i>Cancer Research</i> , 2009, 69, 4443-4453.	0.4	299

#	ARTICLE	IF	CITATIONS
37	Non-invasive ventilation after extubation in hypercapnic patients with chronic respiratory disorders: randomised controlled trial. <i>Lancet</i> , The, 2009, 374, 1082-1088.	6.3	299
38	Microbiologic Determinants of Exacerbation in Chronic Obstructive Pulmonary Disease. <i>Archives of Internal Medicine</i> , 2005, 165, 891.	4.3	259
39	Microbial aetiology of community-acquired pneumonia and its relation to severity. <i>Thorax</i> , 2011, 66, 340-346.	2.7	259
40	Pulmonary exacerbation in adults with bronchiectasis: a consensus definition for clinical research. <i>European Respiratory Journal</i> , 2017, 49, 1700051.	3.1	253
41	Diagnostic Value of Quantitative Cultures of Bronchoalveolar Lavage and Telescoping Plugged Catheters in Mechanically Ventilated Patients with Bacterial Pneumonia. <i>The American Review of Respiratory Disease</i> , 1989, 140, 306-310.	2.9	251
42	Telavancin versus Vancomycin for Hospital-Acquired Pneumonia due to Gram-positive Pathogens. <i>Clinical Infectious Diseases</i> , 2011, 52, 31-40.	2.9	239
43	Relationship between SARS-CoV-2 infection and the incidence of ventilator-associated lower respiratory tract infections: a European multicenter cohort study. <i>Intensive Care Medicine</i> , 2021, 47, 188-198.	3.9	237
44	Etiology of Non-Cystic Fibrosis Bronchiectasis in Adults and Its Correlation to Disease Severity. <i>Annals of the American Thoracic Society</i> , 2015, 12, 1764-1770.	1.5	233
45	Pneumonia. <i>Nature Reviews Disease Primers</i> , 2021, 7, 25.	18.1	230
46	Which individuals are at increased risk of pneumococcal disease and why? Impact of COPD, asthma, smoking, diabetes, and/or chronic heart disease on community-acquired pneumonia and invasive pneumococcal disease: Table A1. <i>Thorax</i> , 2015, 70, 984-989.	2.7	224
47	Bronchial Inflammation and Colonization in Patients with Clinically Stable Bronchiectasis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2001, 164, 1628-1632.	2.5	223
48	An international multicenter retrospective study of <i>Pseudomonas aeruginosa</i> nosocomial pneumonia: impact of multidrug resistance. <i>Critical Care</i> , 2015, 19, 219.	2.5	209
49	Quantitative Cultures of Endotracheal Aspirates for the Diagnosis of Ventilator-associated Pneumonia. <i>The American Review of Respiratory Disease</i> , 1993, 148, 1552-1557.	2.9	206
50	Antimicrobial Treatment Failures in Patients with Community-acquired Pneumonia. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2000, 162, 154-160.	2.5	206
51	Current gaps in sepsis immunology: new opportunities for translational research. <i>Lancet Infectious Diseases</i> , The, 2019, 19, e422-e436.	4.6	205
52	Promoter hypermethylation of cancer-related genes: a strong independent prognostic factor in acute lymphoblastic leukemia. <i>Blood</i> , 2004, 104, 2492-2498.	0.6	204
53	Promoter hypomethylation of the LINE-1 retrotransposable elements activates sense/antisense transcription and marks the progression of chronic myeloid leukemia. <i>Oncogene</i> , 2005, 24, 7213-7223.	2.6	202
54	Automatic control of tracheal tube cuff pressure in ventilated patients in semirecumbent position: A randomized trial*. <i>Critical Care Medicine</i> , 2007, 35, 1543-1549.	0.4	201

#	ARTICLE	IF	CITATIONS
55	Rethinking the concepts of community-acquired and health-care-associated pneumonia. <i>Lancet Infectious Diseases</i> , The, 2010, 10, 279-287.	4.6	196
56	Community-acquired Pneumonia in the Elderly. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1997, 156, 1908-1914.	2.5	192
57	Amoxicillin for acute lower-respiratory-tract infection in primary care when pneumonia is not suspected: a 12-country, randomised, placebo-controlled trial. <i>Lancet Infectious Diseases</i> , The, 2013, 13, 123-129.	4.6	187
58	Multicenter, double-blind, placebo-controlled study of the use of filgrastim in patients hospitalized with pneumonia and severe sepsis*. <i>Critical Care Medicine</i> , 2003, 31, 367-373.	0.4	185
59	Viral RNA load in plasma is associated with critical illness and a dysregulated host response in COVID-19. <i>Critical Care</i> , 2020, 24, 691.	2.5	185
60	Severe Infections after Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplantation in Adults: Comparison of Cord Blood Transplantation with Peripheral Blood and Bone Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 734-748.	2.0	180
61	Programmed "disarming" of the neutrophil proteome reduces the magnitude of inflammation. <i>Nature Immunology</i> , 2020, 21, 135-144.	7.0	180
62	Noninvasive Ventilation in Acute Hypercapnic Respiratory Failure Caused by Obesity Hypoventilation Syndrome and Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012, 186, 1279-1285.	2.5	179
63	Viral Community-Acquired Pneumonia in Nonimmunocompromised Adults. <i>Chest</i> , 2004, 125, 1343-1351.	0.4	174
64	Pneumonia Acquired in the Community Through Drug-Resistant <i>Streptococcus pneumoniae</i> . <i>American Journal of Respiratory and Critical Care Medicine</i> , 1999, 159, 1835-1842.	2.5	171
65	5 CpG island hypermethylation is associated with transcriptional silencing of the p21CIP1/WAF1/SDI1 gene and confers poor prognosis in acute lymphoblastic leukemia. <i>Blood</i> , 2002, 99, 2291-2296.	0.6	171
66	Microbial Etiology of Pneumonia: Epidemiology, Diagnosis and Resistance Patterns. <i>International Journal of Molecular Sciences</i> , 2016, 17, 2120.	1.8	168
67	Pulmonary Function and Radiologic Features in Survivors of Critical COVID-19. <i>Chest</i> , 2021, 160, 187-198.	0.4	164
68	Cytokine expression in severe pneumonia: A bronchoalveolar lavage study. <i>Critical Care Medicine</i> , 1999, 27, 1745-1753.	0.4	164
69	Five day moxifloxacin therapy compared with 7 day clarithromycin therapy for the treatment of acute exacerbations of chronic bronchitis. <i>Journal of Antimicrobial Chemotherapy</i> , 1999, 44, 501-513.	1.3	162
70	Impact of Age and Comorbidity on Cause and Outcome in Community-Acquired Pneumonia. <i>Chest</i> , 2013, 144, 999-1007.	0.4	162
71	Incidence and etiology of pneumonia acquired during mechanical ventilation. <i>Critical Care Medicine</i> , 1989, 17, 882-885.	0.4	161
72	Prospective Study of Prognostic Factors in Community-Acquired Bacteremic Pneumococcal Disease in 5 Countries. <i>Journal of Infectious Diseases</i> , 2000, 182, 840-847.	1.9	161

#	ARTICLE	IF	CITATIONS
73	Specificity of Endotracheal Aspiration, Protected Specimen Brush, and Bronchoalveolar Lavage in Mechanically Ventilated Patients. <i>The American Review of Respiratory Disease</i> , 1993, 147, 952-957.	2.9	160
74	Nosocomial Pneumonia in the Intensive Care Unit Acquired by Mechanically Ventilated versus Nonventilated Patients. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010, 182, 1533-1539.	2.5	160
75	Increased incidence of co-infection in critically ill patients with influenza. <i>Intensive Care Medicine</i> , 2017, 43, 48-58.	3.9	159
76	The Role of Neutrophil Elastase Inhibitors in Lung Diseases. <i>Chest</i> , 2017, 152, 249-262.	0.4	158
77	Global Prospective Epidemiologic and Surveillance Study of Ventilator-Associated Pneumonia due to <i>Pseudomonas aeruginosa</i> *. <i>Critical Care Medicine</i> , 2014, 42, 2178-2187.	0.4	157
78	Diagnostic Value of Telescoping Plugged Catheters in Mechanically Ventilated Patients with Bacterial Pneumonia Using the Metras Catheter. <i>The American Review of Respiratory Disease</i> , 1988, 138, 117-120.	2.9	155
79	Assessment of the Usefulness of Sputum Culture for Diagnosis of Community-Acquired Pneumonia Using the PORT Predictive Scoring System. <i>Archives of Internal Medicine</i> , 2004, 164, 1807.	4.3	154
80	Severe Community-Acquired Pneumonia: Validation of the Infectious Diseases Society of America/American Thoracic Society Guidelines to Predict an Intensive Care Unit Admission. <i>Clinical Infectious Diseases</i> , 2009, 48, 377-385.	2.9	154
81	Guidelines for the Treatment of Community-acquired Pneumonia. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2005, 172, 757-762.	2.5	153
82	Epigenetic regulation of Wnt-signaling pathway in acute lymphoblastic leukemia. <i>Blood</i> , 2007, 109, 3462-3469.	0.6	153
83	Incidence and prognosis of ventilator-associated tracheobronchitis (TAVeM): a multicentre, prospective, observational study. <i>Lancet Respiratory Medicine</i> , 2015, 3, 859-868.	5.2	152
84	Bronchoscopic BAL in the Diagnosis of Ventilator-Associated Pneumonia. <i>Chest</i> , 2000, 117, 198S-202S.	0.4	149
85	Impact of Alcohol Abuse in the Etiology and Severity of Community-Acquired Pneumonia. <i>Chest</i> , 2006, 129, 1219-1225.	0.4	144
86	New Sepsis Definition (Sepsis-3) and Community-acquired Pneumonia Mortality. A Validation and Clinical Decision-Making Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 196, 1287-1297.	2.5	142
87	Drug-Resistant Pneumococcal Pneumonia: Clinical Relevance and Related Factors. <i>Clinical Infectious Diseases</i> , 2004, 38, 787-798.	2.9	138
88	Histopathologic and Microbiologic Aspects of Ventilator-associated Pneumonia. <i>Anesthesiology</i> , 1996, 84, 760-771..	1.3	137
89	Risk Factors Associated with Potentially Antibiotic-Resistant Pathogens in Community-Acquired Pneumonia. <i>Annals of the American Thoracic Society</i> , 2015, 12, 153-160.	1.5	136
90	A Randomized Trial of the Amikacin Fosfomycin Inhalation System for the Adjunctive Therapy of Gram-Negative Ventilator-Associated Pneumonia. <i>Chest</i> , 2017, 151, 1239-1246.	0.4	136

#	ARTICLE	IF	CITATIONS
91	Incidence and prognostic value of FLT3 internal tandem duplication and D835 mutations in acute myeloid leukemia. <i>Haematologica</i> , 2003, 88, 19-24.	1.7	135
92	The EMBARC European Bronchiectasis Registry: protocol for an international observational study. <i>ERJ Open Research</i> , 2016, 2, 00081-2015.	1.1	133
93	Causes and predictors of nonresponse to treatment of intensive care unit-acquired pneumonia*. <i>Critical Care Medicine</i> , 2004, 32, 938-945.	0.4	132
94	Epigenetic Regulation of MicroRNAs in Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2009, 27, 1316-1322.	0.8	131
95	Multidrug-resistant pathogens in hospitalised patients coming from the community with pneumonia: a European perspective: Table A1. <i>Thorax</i> , 2013, 68, 997-999.	2.7	129
96	Reaching Stability in Community-Acquired Pneumonia: The Effects of the Severity of Disease, Treatment, and the Characteristics of Patients. <i>Clinical Infectious Diseases</i> , 2004, 39, 1783-1790.	2.9	128
97	Bronchoscopic validation of the significance of sputum purulence in severe exacerbations of chronic obstructive pulmonary disease. <i>Thorax</i> , 2007, 62, 29-35.	2.7	127
98	Gastric and Pharyngeal Flora in Nosocomial Pneumonia Acquired during Mechanical Ventilation. <i>The American Review of Respiratory Disease</i> , 1993, 148, 352-357.	2.9	123
99	Corticosteroid treatment in critically ill patients with severe influenza pneumonia: a propensity score matching study. <i>Intensive Care Medicine</i> , 2018, 44, 1470-1482.	3.9	123
100	Effect of Almitrine on Ventilation-Perfusion Distribution in Adult Respiratory Distress Syndrome. <i>The American Review of Respiratory Disease</i> , 1988, 137, 1062-1067.	2.9	121
101	Pulmonary Gas Exchange Response to Oxygen Breathing in Acute Lung Injury. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2000, 161, 26-31.	2.5	121
102	Resistance patterns and outcomes in intensive care unit (ICU)-acquired pneumonia. Validation of European Centre for Disease Prevention and Control (ECDC) and the Centers for Disease Control and Prevention (CDC) classification of multidrug resistant organisms. <i>Journal of Infection</i> , 2015, 70, 213-222.	1.7	121
103	An Updated Definition and Severity Classification of Chronic Obstructive Pulmonary Disease Exacerbations: The Rome Proposal. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 204, 1251-1258.	2.5	121
104	Lack of CpG Island Methylator Phenotype Defines a Clinical Subtype of T-Cell Acute Lymphoblastic Leukemia Associated With Good Prognosis. <i>Journal of Clinical Oncology</i> , 2005, 23, 7043-7049.	0.8	120
105	The dynamics of the pulmonary microbiome during mechanical ventilation in the intensive care unit and the association with occurrence of pneumonia. <i>Thorax</i> , 2017, 72, 803-810.	2.7	118
106	Predictors of prolonged weaning and survival during ventilator weaning in a respiratory ICU. <i>Intensive Care Medicine</i> , 2011, 37, 775-784.	3.9	117
107	Prevalence and Etiology of Community-acquired Pneumonia in Immunocompromised Patients. <i>Clinical Infectious Diseases</i> , 2019, 68, 1482-1493.	2.9	116
108	Bronchiectasis in India: results from the European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC) and Respiratory Research Network of India Registry. <i>The Lancet Global Health</i> , 2019, 7, e1269-e1279.	2.9	116

#	ARTICLE	IF	CITATIONS
109	Prognostic Factors of Severe <i>Legionella</i> Pneumonia Requiring Admission to ICU. American Journal of Respiratory and Critical Care Medicine, 1997, 156, 1467-1472.	2.5	115
110	Potentially resistant microorganisms in intubated patients with hospital-acquired pneumonia: the interaction of ecology, shock and risk factors. Intensive Care Medicine, 2013, 39, 672-681.	3.9	114
111	Increased Levels of Tissue Factor mRNA in Mononuclear Blood Cells of Patients with Primary Antiphospholipid Syndrome. Thrombosis and Haemostasis, 1999, 82, 1578-1582.	1.8	110
112	The Role of Viruses in the Aetiology of Community-Acquired Pneumonia in Adults. Antiviral Therapy, 2006, 11, 351-359.	0.6	110
113	Sampling methods for ventilator-associated pneumonia: Validation using different histologic and microbiological references. Critical Care Medicine, 2000, 28, 2799-2804.	0.4	109
114	Global initiative for meticillin-resistant <i>Staphylococcus aureus</i> pneumonia (GLIMP): an international, observational cohort study. Lancet Infectious Diseases, The, 2016, 16, 1364-1376.	4.6	109
115	Procalcitonin (PCT) levels for ruling-out bacterial coinfection in ICU patients with influenza: A CHAID decision-tree analysis. Journal of Infection, 2016, 72, 143-151.	1.7	108
116	Improving Outcomes in Elderly Patients With Community-Acquired Pneumonia by Adhering to National Guidelines. Archives of Internal Medicine, 2009, 169, 1515.	4.3	106
117	Laboratory diagnosis of pneumonia in the molecular age. European Respiratory Journal, 2016, 48, 1764-1778.	3.1	106
118	Prospective Comparison of Severity Scores for Predicting Clinically Relevant Outcomes for Patients Hospitalized With Community-Acquired Pneumonia. Chest, 2009, 135, 1572-1579.	0.4	105
119	Treatment of Community-Acquired Pneumonia in Immunocompromised Adults. Chest, 2020, 158, 1896-1911.	0.4	105
120	Prognostic power of proadrenomedullin in community-acquired pneumonia is independent of aetiology. European Respiratory Journal, 2012, 39, 1144-1155.	3.1	104
121	Pneumonia Severity Index Class V Patients With Community-Acquired Pneumonia. Chest, 2007, 132, 515-522.	0.4	103
122	The intensive care medicine research agenda on multidrug-resistant bacteria, antibiotics, and stewardship. Intensive Care Medicine, 2017, 43, 1187-1197.	3.9	103
123	Mechanisms of Hypoxemia in Patients with Status Asthmaticus Requiring Mechanical Ventilation. The American Review of Respiratory Disease, 1989, 139, 732-739.	2.9	102
124	Murepavadin: a new antibiotic class in the pipeline. Expert Review of Anti-Infective Therapy, 2018, 16, 259-268.	2.0	100
125	Challenges in severe community-acquired pneumonia: a point-of-view review. Intensive Care Medicine, 2019, 45, 159-171.	3.9	100
126	Community-acquired polymicrobial pneumonia in the intensive care unit: aetiology and prognosis. Critical Care, 2011, 15, R209.	2.5	99



#	ARTICLE	IF	CITATIONS
127	Inflammatory biomarkers and prediction for intensive care unit admission in severe community-acquired pneumonia*. <i>Critical Care Medicine</i> , 2011, 39, 2211-2217.	0.4	99
128	Corticosteroids in Patients Hospitalized With Community-Acquired Pneumonia: Systematic Review and Individual Patient Data Metaanalysis. <i>Clinical Infectious Diseases</i> , 2018, 66, 346-354.	2.9	98
129	Diagnosis of ventilator-associated pneumonia in critically ill adult patients—a systematic review and meta-analysis. <i>Intensive Care Medicine</i> , 2020, 46, 1170-1179.	3.9	98
130	Comparison of antimicrobial cycling and mixing strategies in two medical intensive care units*. <i>Critical Care Medicine</i> , 2006, 34, 329-336.	0.4	97
131	Efficacy and safety of trimodulin, a novel polyclonal antibody preparation, in patients with severe community-acquired pneumonia: a randomized, placebo-controlled, double-blind, multicenter, phase II trial (CIGMA study). <i>Intensive Care Medicine</i> , 2018, 44, 438-448.	3.9	96
132	Molecular Epidemiology of <i>Streptococcus pneumoniae</i> Causing Invasive Disease in 5 Countries. <i>Journal of Infectious Diseases</i> , 2000, 182, 833-839.	1.9	95
133	Treatment Guidelines and Outcomes of Hospital-Acquired and Ventilator-Associated Pneumonia. <i>Clinical Infectious Diseases</i> , 2010, 51, S48-S53.	2.9	95
134	Advances in antibiotic therapy in the critically ill. <i>Critical Care</i> , 2016, 20, 133.	2.5	94
135	The burden of community-acquired bacterial pneumonia in the era of antibiotic resistance. <i>Expert Review of Respiratory Medicine</i> , 2019, 13, 139-152.	1.0	92
136	Nebulized antibiotics for ventilator-associated pneumonia: a systematic review and meta-analysis. <i>Critical Care</i> , 2015, 19, 150.	2.5	91
137	Ventilation-Perfusion Mismatching in Chronic Obstructive Pulmonary Disease during Ventilator Weaning. <i>The American Review of Respiratory Disease</i> , 1989, 140, 1246-1250.	2.9	90
138	Pneumonic and Nonpneumonic Exacerbations of COPD. <i>Chest</i> , 2013, 144, 1134-1142.	0.4	90
139	Burden of pneumococcal community-acquired pneumonia in adults across Europe: A literature review. <i>Respiratory Medicine</i> , 2018, 137, 6-13.	1.3	90
140	Lymphopenic community acquired pneumonia as signature of severe COVID-19 infection. <i>Journal of Infection</i> , 2020, 80, e23-e24.	1.7	89
141	Population Pharmacokinetics of High-Dose Methotrexate in Children with Acute Lymphoblastic Leukaemia. <i>Clinical Pharmacokinetics</i> , 2006, 45, 1227-1238.	1.6	86
142	Predictors of Adverse Outcome in Patients Hospitalised for Exacerbation of Chronic Obstructive Pulmonary Disease. <i>Respiration</i> , 2012, 84, 17-26.	1.2	86
143	Cytokine Activation Patterns and Biomarkers Are Influenced by Microorganisms in Community-Acquired Pneumonia. <i>Chest</i> , 2012, 141, 1537-1545.	0.4	86
144	Diagnosis of infection in sepsis: An evidence-based review. <i>Critical Care Medicine</i> , 2004, 32, S466-S494.	0.4	85

#	ARTICLE	IF	CITATIONS
145	Risk and prognostic factors of ventilator-associated pneumonia in trauma patients. <i>Critical Care Medicine</i> , 2006, 34, 1067-1072.	0.4	85
146	Adequacy of Antimicrobial Treatment and Outcome of <i>Staphylococcus aureus</i> Bacteremia in 9 Western European Countries. <i>Clinical Infectious Diseases</i> , 2009, 49, 997-1005.	2.9	85
147	Community-Acquired Pneumonia Due to Multidrug- and Non-Multidrug-Resistant <i>Pseudomonas aeruginosa</i> . <i>Chest</i> , 2016, 150, 415-425.	0.4	85
148	Community-acquired pneumonia related to intracellular pathogens. <i>Intensive Care Medicine</i> , 2016, 42, 1374-1386.	3.9	85
149	Molecular analysis of lineage-specific chimerism and minimal residual disease by RT-PCR of p210BCR-ABL and p190BCR-ABL after allogeneic bone marrow transplantation for chronic myeloid leukemia: increasing mixed myeloid chimerism and p190BCR-ABL detection precede cytogenetic relapse. <i>Blood</i> , 2000, 95, 2659-2665.	0.6	83
150	Intensive care unit-acquired pneumonia due to <i>Pseudomonas aeruginosa</i> with and without multidrug resistance. <i>Journal of Infection</i> , 2017, 74, 142-152.	1.7	83
151	SEVERE COMMUNITY-ACQUIRED PNEUMONIA. <i>Clinics in Chest Medicine</i> , 1999, 20, 575-587.	0.8	82
152	Diagnosing Ventilator-Associated Pneumonia. <i>New England Journal of Medicine</i> , 2004, 350, 433-435.	13.9	82
153	A Prediction Rule for Estimating the Risk of Bacteremia in Patients with Community-Acquired Pneumonia. <i>Clinical Infectious Diseases</i> , 2009, 49, 409-416.	2.9	82
154	Updated guidance on the management of COVID-19: from an American Thoracic Society/European Respiratory Society coordinated International Task Force (29 July 2020). <i>European Respiratory Review</i> , 2020, 29, 200287.	3.0	82
155	Nosocomial Infection. <i>Critical Care Medicine</i> , 2021, 49, 169-187.	0.4	82
156	Severe community-acquired pneumonia: Characteristics and prognostic factors in ventilated and non-ventilated patients. <i>PLoS ONE</i> , 2018, 13, e0191721.	1.1	81
157	Pulmonary Infiltrates in Patients Receiving Long-term Glucocorticoid Treatment*. <i>Chest</i> , 2003, 123, 488-498.	0.4	80
158	Prognostic Factors of Non-HIV Immunocompromised Patients With Pulmonary Infiltrates. <i>Chest</i> , 2002, 122, 253-261.	0.4	78
159	Microbial airway colonization is associated with noninvasive ventilation failure in exacerbation of chronic obstructive pulmonary disease*. <i>Critical Care Medicine</i> , 2005, 33, 2003-2009.	0.4	78
160	Towards a sensible comprehension of severe community-acquired pneumonia. <i>Intensive Care Medicine</i> , 2011, 37, 214-223.	3.9	78
161	Efficacy of Corticosteroid Therapy in Patients With an Acute Exacerbation of Chronic Obstructive Pulmonary Disease Receiving Ventilatory Support. <i>Archives of Internal Medicine</i> , 2011, 171, 1939.	4.3	78
162	Multidrug Resistant Gram-Negative Bacteria in Community-Acquired Pneumonia. <i>Critical Care</i> , 2019, 23, 79.	2.5	78

#	ARTICLE	IF	CITATIONS
163	Bacterial co-infection with H1N1 infection in patients admitted with community acquired pneumonia. <i>Journal of Infection</i> , 2012, 65, 223-230.	1.7	77
164	Microbial aetiology of healthcare associated pneumonia in Spain: a prospective, multicentre, caseâ€“control study. <i>Thorax</i> , 2013, 68, 1007-1014.	2.7	77
165	New guidelines for hospital-acquired pneumonia/ventilator-associated pneumonia: USA vs. Europe. <i>Current Opinion in Critical Care</i> , 2018, 24, 347-352.	1.6	77
166	Epigenetic down-regulation of BIM expression is associated with reduced optimal responses to imatinib treatment in chronic myeloid leukaemia. <i>European Journal of Cancer</i> , 2009, 45, 1877-1889.	1.3	76
167	Sputum purulence-guided antibiotic use in hospitalised patients with exacerbations of COPD. <i>European Respiratory Journal</i> , 2012, 40, 1344-1353.	3.1	76
168	Moxifloxacin Monotherapy Is Effective in Hospitalized Patients with Communityâ€“Acquired Pneumonia: The MOTIV Studyâ€“A Randomized Clinical Trial. <i>Clinical Infectious Diseases</i> , 2008, 46, 1499-1509.	2.9	75
169	Hypophosphatemia as a cause of failed weaning. <i>Critical Care Medicine</i> , 1984, 12, 142-143.	0.4	74
170	Treatment Failure in Community-Acquired Pneumonia. <i>Chest</i> , 2007, 132, 1348-1355.	0.4	73
171	Diagnostic Value of Nonfluoroscopic Percutaneous Lung Needle Aspiration in Patients with Pneumonia. <i>Chest</i> , 1990, 98, 840-844.	0.4	72
172	Readmission for Acute Exacerbation within 30 Days of Discharge Is Associated with a Subsequent Progressive Increase in Mortality Risk in COPD Patients: A Long-Term Observational Study. <i>PLoS ONE</i> , 2016, 11, e0150737.	1.1	72
173	In-Laboratory Removal of Femoral Sheath Following Protamine Administration in Patients Having Intracoronary Stent Implantation. <i>American Journal of Cardiology</i> , 1997, 80, 1336-1338.	0.7	71
174	Decrease in Mortality in Severe Community-Acquired Pneumococcal Pneumonia. <i>Chest</i> , 2014, 146, 22-31.	0.4	71
175	Bronchial Colonization and Postoperative Respiratory Infections in Patients Undergoing Lung Cancer Surgery. <i>Chest</i> , 2005, 128, 1571-1579.	0.4	70
176	Criteria and definitions for the radiological and clinical diagnosis of bronchiectasis in adults for use in clinical trials: international consensus recommendations. <i>Lancet Respiratory Medicine</i> , 2022, 10, 298-306.	5.2	70
177	Lymphopenic Community Acquired Pneumonia (L-CAP), an Immunological Phenotype Associated with Higher Risk of Mortality. <i>EBioMedicine</i> , 2017, 24, 231-236.	2.7	69
178	Pulmonary infections complicating ARDS. <i>Intensive Care Medicine</i> , 2020, 46, 2168-2183.	3.9	69
179	Relationship between ventilator-associated pneumonia and mortality in COVID-19 patients: a planned ancillary analysis of the coVAPid cohort. <i>Critical Care</i> , 2021, 25, 177.	2.5	69
180	Pulmonary Infiltrates in Immunocompromised Patients. <i>Chest</i> , 1989, 95, 130-135.	0.4	68

#	ARTICLE	IF	CITATIONS
181	COVID-19 as a cardiovascular disease: the potential role of chronic endothelial dysfunction. <i>Cardiovascular Research</i> , 2020, 116, e132-e133.	1.8	68
182	Non-infectious and unusual infectious mimics of community-acquired pneumonia. <i>Respiratory Medicine</i> , 2004, 98, 488-494.	1.3	67
183	Epidemiology of ICU-acquired pneumonia. <i>Current Opinion in Critical Care</i> , 2018, 24, 325-331.	1.6	67
184	WNT5A, a putative tumour suppressor of lymphoid malignancies, is inactivated by aberrant methylation in acute lymphoblastic leukaemia. <i>European Journal of Cancer</i> , 2007, 43, 2736-2746.	1.3	66
185	Validation of the American Thoracic Society's Infectious Diseases Society of America Guidelines for Hospital-Acquired Pneumonia in the Intensive Care Unit. <i>Clinical Infectious Diseases</i> , 2010, 50, 945-952.	2.9	66
186	Meropenem Population Pharmacokinetics in Critically Ill Patients with Septic Shock and Continuous Renal Replacement Therapy: Influence of Residual Diuresis on Dose Requirements. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 5520-5528.	1.4	66
187	Early Bacterial Identification among Intubated Patients with COVID-19 or Influenza Pneumonia: A European Multicenter Comparative Clinical Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 204, 546-556.	2.5	65
188	Community-acquired pneumonia in outpatients: aetiology and outcomes. <i>European Respiratory Journal</i> , 2012, 40, 931-938.	3.1	64
189	Gastric intramucosal acidosis in mechanically ventilated patients. <i>Critical Care Medicine</i> , 1998, 26, 827-832.	0.4	64
190	Etiology and Microbial Patterns of Pulmonary Infiltrates in Patients With Orthotopic Liver Transplantation. <i>Chest</i> , 2000, 117, 494-502.	0.4	63
191	CpG Island Methylator Phenotype Redefines the Prognostic Effect of t(12;21) in Childhood Acute Lymphoblastic Leukemia. <i>Clinical Cancer Research</i> , 2006, 12, 4845-4850.	3.2	62
192	Predictors of Severe Sepsis among Patients Hospitalized for Community-Acquired Pneumonia. <i>PLoS ONE</i> , 2016, 11, e0145929.	1.1	61
193	Visceral and somatic pain modalities reveal $N_{aV}1.7$ independent visceral nociceptive pathways. <i>Journal of Physiology</i> , 2017, 595, 2661-2679.	1.3	61
194	Management of severe acute exacerbations of COPD: an updated narrative review. <i>Multidisciplinary Respiratory Medicine</i> , 2018, 13, 36.	0.6	61
195	Disparity for the minor histocompatibility antigen HA-1 is associated with an increased risk of acute graft-versus-host disease (GvHD) but it does not affect chronic GvHD incidence, disease-free survival or overall survival after allogeneic human leucocyte. <i>British Journal of Haematology</i> , 2001, 114, 931-936.	1.2	60
196	Proteomic analysis of acute myeloid leukemia: Identification of potential early biomarkers and therapeutic targets. <i>Proteomics</i> , 2006, 6, S293-S299.	1.3	60
197	Poor prognosis in acute lymphoblastic leukemia may relate to promoter hypermethylation of cancer-related genes. <i>Leukemia and Lymphoma</i> , 2007, 48, 1269-1282.	0.6	60
198	Is healthcare-associated pneumonia a distinct entity needing specific therapy?. <i>Current Opinion in Infectious Diseases</i> , 2012, 25, 166-175.	1.3	60

#	ARTICLE	IF	CITATIONS
199	Validation of Predictors of Adverse Outcomes in Hospital-Acquired Pneumonia in the ICU*. Critical Care Medicine, 2013, 41, 2151-2161.	0.4	60
200	The Effect of Macrolide Resistance on the Presentation and Outcome of Patients Hospitalized for <i>Streptococcus pneumoniae</i> Pneumonia. American Journal of Respiratory and Critical Care Medicine, 2015, 191, 1265-1272.	2.5	59
201	Systemic Biomarkers of Collagen and Elastin Turnover Are Associated With Clinically Relevant Outcomes in COPD. Chest, 2017, 151, 47-59.	0.4	59
202	Colour of sputum is a marker for bacterial colonisation in chronic obstructive pulmonary disease. Respiratory Research, 2010, 11, 58.	1.4	58
203	Community-acquired lung respiratory infections in HIV-infected patients: microbial aetiology and outcome. European Respiratory Journal, 2014, 43, 1698-1708.	3.1	58
204	The role of viruses in the aetiology of community-acquired pneumonia in adults. Antiviral Therapy, 2006, 11, 351-9.	0.6	58
205	MicroRNAs Expressed during Lung Cancer Development Are Expressed in Human Pseudoglandular Lung Embryogenesis. Oncology, 2009, 76, 162-169.	0.9	57
206	Epidemiology, antibiotic therapy and clinical outcomes of healthcare-associated pneumonia in critically ill patients: a Spanish cohort study. Intensive Care Medicine, 2014, 40, 572-581.	3.9	57
207	Pandemic and post-pandemic Influenza A (H1N1) infection in critically ill patients. Critical Care, 2011, 15, R286.	2.5	56
208	Pathophysiology of Pneumonia. Clinics in Chest Medicine, 2005, 26, 39-46.	0.8	55
209	Mechanisms of Abnormal Gas Exchange in Patients with Pneumonia. Anesthesiology, 1991, 75, 782-789.	1.3	54
210	Endothelial adhesion molecules and multiple organ failure in patients with severe sepsis. Cytokine, 2016, 88, 267-273.	1.4	54
211	Impact of neuraminidase inhibitors on influenza A(H1N1)pdm09-related pneumonia: an individual participant data meta-analysis. Influenza and Other Respiratory Viruses, 2016, 10, 192-204.	1.5	54
212	Aerosolized $\beta_2$ -agonists in the intensive care unit: just do it. Intensive Care Medicine, 2001, 27, 3-5.	3.9	53
213	Deregulation of <i>FGFR1</i> and <i>CDK6</i> oncogenic pathways in acute lymphoblastic leukaemia harbouring epigenetic modifications of the <i>MIR9</i> family. British Journal of Haematology, 2011, 155, 73-83.	1.2	53
214	Effects of duty cycle and positive end-expiratory pressure on mucus clearance during mechanical ventilation*. Critical Care Medicine, 2012, 40, 895-902.	0.4	53
215	Developing definitions for invasive fungal diseases in critically ill adult patients in intensive care units. Protocol of the FUNgal infections Definitions in ICU patients (FUNDICU) project. Mycoses, 2019, 62, 310-319.	1.8	53
216	Procalcitonin and C-Reactive Protein for Invasive Bacterial Pneumonia Diagnosis among Children in Mozambique, a Malaria-Endemic Area. PLoS ONE, 2010, 5, e13226.	1.1	52

#	ARTICLE	IF	CITATIONS
217	Ventilator-Associated Pneumonia. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2014, 35, 469-481.	0.8	52
218	Frequent and Simultaneous Epigenetic Inactivation of TP53 Pathway Genes in Acute Lymphoblastic Leukemia. <i>PLoS ONE</i> , 2011, 6, e17012.	1.1	52
219	An In Vitro Study to Assess Determinant Features Associated With Fluid Sealing in the Design of Endotracheal Tube Cuffs and Exerted Tracheal Pressures*. <i>Critical Care Medicine</i> , 2013, 41, 518-526.	0.4	51
220	Sensitivity, Specificity, and Positivity Predictors of the Pneumococcal Urinary Antigen Test in Community-Acquired Pneumonia. <i>Annals of the American Thoracic Society</i> , 2015, 12, 1482-1489.	1.5	51
221	Pulmonary Infiltrates in HIV-Infected Patients in the Highly Active Antiretroviral Therapy Era in Spain. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2001, 27, 35-43.	0.9	50
222	Viral pneumonia. <i>Current Opinion in Infectious Diseases</i> , 2009, 22, 143-147.	1.3	50
223	Biomarker kinetics in the prediction of VAP diagnosis: results from the BioVAP study. <i>Annals of Intensive Care</i> , 2016, 6, 32.	2.2	50
224	Systemic Inflammatory Pattern of Patients With Community-Acquired Pneumonia With and Without COPD. <i>Chest</i> , 2013, 143, 1009-1017.	0.4	49
225	<i>Pneumocystis</i> pneumonia in the twenty-first century: HIV-infected versus HIV-uninfected patients. <i>Expert Review of Anti-Infective Therapy</i> , 2019, 17, 787-801.	2.0	49
226	Evidence-Based Study Design for Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia. <i>Journal of Infectious Diseases</i> , 2019, 219, 1536-1544.	1.9	49
227	Pulmonary Infiltrates in Immunosuppressed Patients: Analysis of a Diagnostic Protocol. <i>Journal of Clinical Microbiology</i> , 2002, 40, 2134-2140.	1.8	48
228	Prevention measures for ventilator-associated pneumonia: a new focus on the endotracheal tube. <i>Current Opinion in Infectious Diseases</i> , 2007, 20, 190-197.	1.3	48
229	Influence of Previous Use of Inhaled Corticoids on the Development of Pleural Effusion in Community-acquired Pneumonia. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013, 187, 1241-1248.	2.5	48
230	Effects of bronchoalveolar lavage volume on arterial oxygenation in mechanically ventilated patients with pneumonia. <i>Intensive Care Medicine</i> , 2001, 27, 384-393.	3.9	47
231	Disposition of instilled versus nebulized tobramycin and imipenem in ventilated intensive care unit (ICU) patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2004, 54, 508-514.	1.3	47
232	Ventilator-associated pneumonia: role of positioning. <i>Current Opinion in Critical Care</i> , 2011, 17, 57-63.	1.6	47
233	Thrombocytosis Is a Marker of Poor Outcome in Community-Acquired Pneumonia. <i>Chest</i> , 2013, 143, 767-775.	0.4	47
234	Continuous control of tracheal cuff pressure for VAP prevention: a collaborative meta-analysis of individual participant data. <i>Annals of Intensive Care</i> , 2015, 5, 43.	2.2	47

#	ARTICLE	IF	CITATIONS
235	Core Outcomes Set for Trials in People With Coronavirus Disease 2019. <i>Critical Care Medicine</i> , 2020, 48, 1622-1635.	0.4	47
236	Microbiologic features and outcome of pneumonia in transplanted patients. <i>Diagnostic Microbiology and Infectious Disease</i> , 2006, 55, 47-54.	0.8	46
237	Evaluation of the 2016 Infectious Diseases Society of America/American Thoracic Society Guideline Criteria for Risk of Multidrug-Resistant Pathogens in Patients with Hospital-acquired and Ventilator-associated Pneumonia in the ICU. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 197, 826-830.	2.5	46
238	Invasive pulmonary aspergillosis among intubated patients with SARS-CoV-2 or influenza pneumonia: a European multicenter comparative cohort study. <i>Critical Care</i> , 2022, 26, 11.	2.5	46
239	Acute respiratory distress syndrome in mechanically ventilated patients with community-acquired pneumonia. <i>European Respiratory Journal</i> , 2018, 51, 1702215.	3.1	45
240	Lymphopenic community-acquired pneumonia is associated with a dysregulated immune response and increased severity and mortality. <i>Journal of Infection</i> , 2019, 78, 423-431.	1.7	45
241	The BRICS (Bronchiectasis Radiologically Indexed CT Score). <i>Chest</i> , 2018, 153, 1177-1186.	0.4	44
242	Ventilator-associated pneumonia. <i>Current Opinion in Critical Care</i> , 2009, 15, 30-35.	1.6	43
243	Epigenetic regulation of the non-canonical Wnt pathway in acute myeloid leukemia. <i>Cancer Science</i> , 2010, 101, 425-432.	1.7	43
244	Seasonality of pathogens causing community-acquired pneumonia. <i>Respirology</i> , 2017, 22, 778-785.	1.3	43
245	Chest physiotherapy: An important adjuvant in critically ill mechanically ventilated patients with COVID-19. <i>Respiratory Physiology and Neurobiology</i> , 2020, 282, 103529.	0.7	43
246	Community-acquired pneumonia in critically ill very old patients: a growing problem. <i>European Respiratory Review</i> , 2020, 29, 190126.	3.0	43
247	Importance of <i>Aspergillus</i> spp. isolation in Acute exacerbations of severe COPD: prevalence, factors and follow-up: the FUNGI-COPD study. <i>Respiratory Research</i> , 2014, 15, 17.	1.4	42
248	Assessment of Severity of ICU-Acquired Pneumonia and Association With Etiology. <i>Critical Care Medicine</i> , 2014, 42, 303-312.	0.4	42
249	Bacteraemia and antibiotic-resistant pathogens in community acquired pneumonia: risk and prognosis. <i>European Respiratory Journal</i> , 2015, 45, 1353-1363.	3.1	42
250	What is the clinical relevance of drug-resistant pneumococcus?. <i>Current Opinion in Pulmonary Medicine</i> , 2016, 22, 227-234.	1.2	42
251	Pharmacokinetics and Dosing of Ceftobiprole Medocaril for the Treatment of Hospital- and Community-Acquired Pneumonia in Different Patient Populations. <i>Clinical Pharmacokinetics</i> , 2016, 55, 1507-1520.	1.6	42
252	Collagen Degradation and Formation Are Elevated in Exacerbated COPD Compared With Stable Disease. <i>Chest</i> , 2018, 154, 798-807.	0.4	42

#	ARTICLE	IF	CITATIONS
253	COMMUNITY-ACQUIRED PNEUMONIA IN THE INTENSIVE CARE UNIT. <i>Clinics in Chest Medicine</i> , 1995, 16, 155-171.	0.8	42
254	Experimental Severe <i>Pseudomonas aeruginosa</i> Pneumonia and Antibiotic Therapy in Piglets Receiving Mechanical Ventilation. <i>Chest</i> , 2007, 132, 523-531.	0.4	41
255	Effects of Manual Rib Cage Compressions on Expiratory Flow and Mucus Clearance During Mechanical Ventilation*. <i>Critical Care Medicine</i> , 2013, 41, 850-856.	0.4	41
256	Adrenomedullin refines mortality prediction by the BODE index in COPD: the "BODE-A" index. <i>European Respiratory Journal</i> , 2014, 43, 397-408.	3.1	41
257	A Worldwide Perspective of Nursing Home-Acquired Pneumonia Compared With Community-Acquired Pneumonia. <i>Respiratory Care</i> , 2014, 59, 1078-1085.	0.8	41
258	Polymicrobial intensive care unit-acquired pneumonia: prevalence, microbiology and outcome. <i>Critical Care</i> , 2015, 19, 450.	2.5	41
259	A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Iclaprim Vs Vancomycin for the Treatment of Acute Bacterial Skin and Skin Structure Infections Suspected or Confirmed to be Due to Gram-Positive Pathogens: REVIVE-1. <i>Clinical Infectious Diseases</i> , 2018, 66, 1222-1229.	2.9	41
260	Community-acquired pneumonia as an emergency condition. <i>Current Opinion in Critical Care</i> , 2018, 24, 531-539.	1.6	41
261	Summary of the international clinical guidelines for the management of hospital-acquired and ventilator-acquired pneumonia. <i>ERJ Open Research</i> , 2018, 4, 00028-2018.	1.1	41
262	Core Outcome Measures for Trials in People With Coronavirus Disease 2019: Respiratory Failure, Multiorgan Failure, Shortness of Breath, and Recovery. <i>Critical Care Medicine</i> , 2021, 49, 503-516.	0.4	41
263	Initial Inflammatory Profile in Community-acquired Pneumonia Depends on Time since Onset of Symptoms. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 198, 370-378.	2.5	40
264	Community-Acquired Pneumonia Patients at Risk for Early and Long-term Cardiovascular Events Are Identified by Cardiac Biomarkers. <i>Chest</i> , 2019, 156, 1080-1091.	0.4	40
265	Lipid deposition during the long-term infusion of propofol. <i>Critical Care Medicine</i> , 1995, 23, 1928-1930.	0.4	40
266	Acute respiratory failure and tracheal obstruction in patients with intrathoracic goiter. <i>Critical Care Medicine</i> , 1983, 11, 265-266.	0.4	39
267	Bronchoalveolar Lavage to Diagnose Respiratory Infections. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2007, 28, 525-533.	0.8	39
268	Phenotyping community-acquired pneumonia according to the presence of acute respiratory failure and severe sepsis. <i>Respiratory Research</i> , 2014, 15, 27.	1.4	39
269	Declining Mortality in Patients With Acute Respiratory Distress Syndrome: An Analysis of the Acute Respiratory Distress Syndrome Network Trials. <i>Critical Care Medicine</i> , 2019, 47, 315-323.	0.4	39
270	Common Variants of TLR1 Associate with Organ Dysfunction and Sustained Pro-Inflammatory Responses during Sepsis. <i>PLoS ONE</i> , 2010, 5, e13759.	1.1	39



#	ARTICLE	IF	CITATIONS
271	Evaluation of antimicrobial treatment in mechanically ventilated patients with severe chronic obstructive pulmonary disease exacerbations. <i>Critical Care Medicine</i> , 2000, 28, 692-697.	0.4	38
272	Hospitalized Community-Acquired Pneumonia Due to <i>Streptococcus pneumoniae</i> . <i>Chest</i> , 2006, 130, 800-806.	0.4	38
273	Experience with pneumococcal polysaccharide conjugate vaccine (conjugated to CRM197 carrier) Tj ETQq1 1 0.784314 rgBT/Overlo	2.8	38
274	Antibiotic Prescribing for Acute Respiratory Tract Infections 12 Months After Communication and CRP Training: A Randomized Trial. <i>Annals of Family Medicine</i> , 2019, 17, 125-132.	0.9	38
275	Hantavirus Pulmonary Syndrome, Southern Chile. <i>Emerging Infectious Diseases</i> , 2003, 9, 1438-1443.	2.0	37
276	Biomarkers and Community-Acquired Pneumonia: Tailoring Management with Biological Data. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2012, 33, 266-271.	0.8	37
277	Efficacy of linezolid compared to vancomycin in an experimental model of pneumonia induced by methicillin-resistant <i>Staphylococcus aureus</i> in ventilated pigs*. <i>Critical Care Medicine</i> , 2012, 40, 162-168.	0.4	37
278	Concept for a study design in patients with severe community-acquired pneumonia: A randomised controlled trial with a novel IGM-enriched immunoglobulin preparation â€œ The CIGMA study. <i>Respiratory Medicine</i> , 2015, 109, 758-767.	1.3	37
279	Prognostic assessment in COPD without lung function: the B-AE-D indices. <i>European Respiratory Journal</i> , 2016, 47, 1635-1644.	3.1	37
280	Biofilms in ventilator-associated pneumonia. <i>Future Microbiology</i> , 2016, 11, 1599-1610.	1.0	37
281	Measures to prevent nosocomial infections during mechanical ventilation. <i>Current Opinion in Critical Care</i> , 2012, 18, 86-92.	1.6	36
282	Association between systemic corticosteroids and outcomes of intensive care unitâ€œacquired pneumonia*. <i>Critical Care Medicine</i> , 2012, 40, 2552-2561.	0.4	36
283	Trust, openness and continuity of care influence acceptance of antibiotics for children with respiratory tract infections: a four country qualitative study. <i>Family Practice</i> , 2014, 31, 102-110.	0.8	36
284	Noninvasive ventilation for acute respiratory failure. <i>Current Opinion in Critical Care</i> , 2015, 21, 1-6.	1.6	36
285	Predictive and prognostic factors in patients with blood-culture-positive community-acquired pneumococcal pneumonia. <i>European Respiratory Journal</i> , 2016, 48, 797-807.	3.1	36
286	Randomized, multicenter trial of lateral Trendelenburg versus semirecumbent body position for the prevention of ventilator-associated pneumonia. <i>Intensive Care Medicine</i> , 2017, 43, 1572-1584.	3.9	36
287	Phenotypic shift in <i>Pseudomonas aeruginosa</i> populations from cystic fibrosis lungs after 2-week antipseudomonal treatment. <i>Journal of Cystic Fibrosis</i> , 2017, 16, 222-229.	0.3	36
288	The importance of airway and lung microbiome in the critically ill. <i>Critical Care</i> , 2020, 24, 537.	2.5	36

#	ARTICLE	IF	CITATIONS
289	RESPIRATORY INFECTIOUS COMPLICATIONS IN THE INTENSIVE CARE UNIT. Clinics in Chest Medicine, 1999, 20, 287-301.	0.8	35
290	Initial Bacterial Colonization in Patients Admitted to a Respiratory Intensive Care Unit: Bacteriological Pattern and Risk Factors. Respiration, 2001, 68, 58-66.	1.2	35
291	Validation and comparison of SCAP as a predictive score for identifying low-risk patients in community-acquired pneumonia. Journal of Infection, 2010, 60, 106-113.	1.7	35
292	Randomized Trial of Ceftazidime-Avibactam vs Meropenem for Treatment of Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (REPROVE): Analyses per US FDA's Specified End Points. Open Forum Infectious Diseases, 2019, 6, ofz149.	0.4	35
293	Trends in mortality of hospitalised COVID-19 patients: A single centre observational cohort study from Spain. Lancet Regional Health - Europe, The, 2021, 3, 100041.	3.0	35
294	Inhibition of Flt3-activating mutations does not prevent constitutive activation of ERK/Akt/STAT pathways in some AML cells: a possible cause for the limited effectiveness of monotherapy with small-molecule inhibitors. Hematological Oncology, 2007, 25, 30-37.	0.8	34
295	<i>Pseudomonas aeruginosa</i> Nosocomial Pneumonia: Impact of Pneumonia Classification. Infection Control and Hospital Epidemiology, 2015, 36, 1190-1197.	1.0	34
296	Pneumococcal vaccination. Current Opinion in Infectious Diseases, 2016, 29, 187-196.	1.3	34
297	Effect of Combined $\beta$ -Lactam/Macrolide Therapy on Mortality According to the Microbial Etiology and Inflammatory Status of Patients With Community-Acquired Pneumonia. Chest, 2019, 155, 795-804.	0.4	34
298	Neumonía adquirida en la comunidad. Normativa de la Sociedad Española de Neumología y Cirugía Torácica (SEPAR). Actualización 2020. Archivos De Bronconeumología, 2020, 56, 1-10.	0.4	34
299	Detection of Pneumonia Associated Pathogens Using a Prototype Multiplexed Pneumonia Test in Hospitalized Patients with Severe Pneumonia. PLoS ONE, 2014, 9, e110566.	1.1	34
300	STREPTOCOCCUS PNEUMONIAE IN COMMUNITY-AQUIRED PNEUMONIA. Medical Clinics of North America, 2001, 85, 1367-1379.	1.1	33
301	Treatment of acute cough/lower respiratory tract infection by antibiotic class and associated outcomes: a 13 European country observational study in primary care. Journal of Antimicrobial Chemotherapy, 2010, 65, 2472-2478.	1.3	33
302	No More Equivalence Trials for Antibiotics in Exacerbations of COPD, Please. Chest, 2004, 125, 811-813.	0.4	32
303	Update in Community-acquired and Nosocomial Pneumonia 2009. American Journal of Respiratory and Critical Care Medicine, 2010, 181, 782-787.	2.5	32
304	A Novel Porcine Model of Ventilator-associated Pneumonia Caused by Oropharyngeal Challenge with <i>Pseudomonas aeruginosa</i> . Anesthesiology, 2014, 120, 1205-1215.	1.3	32
305	Therapy with proton pump inhibitors for gastroesophageal reflux disease does not reduce the risk for severe exacerbations in COPD. Respirology, 2016, 21, 883-890.	1.3	32
306	Impact of Hypertonic Saline Solutions on Sputum Expectoration and Their Safety Profile in Patients with Bronchiectasis: A Randomized Crossover Trial. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2018, 31, 281-289.	0.7	32

#	ARTICLE	IF	CITATIONS
307	Comparison of two prognostic scores (BSI and FACED) in a Spanish cohort of adult patients with bronchiectasis and improvement of the FACED predictive capacity for exacerbations. <i>PLoS ONE</i> , 2017, 12, e0175171.	1.1	32
308	Gender differences in community-acquired pneumonia. <i>Minerva Medica</i> , 2020, 111, 153-165.	0.3	32
309	Hospital-acquired pneumonia: etiologic considerations. <i>Infectious Disease Clinics of North America</i> , 2003, 17, 679-695.	1.9	31
310	Systemic inflammatory response and increased risk for ventilator-associated pneumonia: A preliminary study. <i>Critical Care Medicine</i> , 2009, 37, 1691-1695.	0.4	31
311	Community-Acquired Pneumonia. New Guidelines of the Spanish Society of Pulmonology and Thoracic Surgery (SEPAR). <i>Archivos De Bronconeumologia</i> , 2010, 46, 543-558.	0.4	31
312	Systemic corticosteroids for community-acquired pneumonia: Reasons for use and lack of benefit on outcome. <i>Respirology</i> , 2013, 18, 263-271.	1.3	31
313	Inflammatory response in mixed viral-bacterial community-acquired pneumonia. <i>BMC Pulmonary Medicine</i> , 2014, 14, 123.	0.8	31
314	Polymicrobial community-acquired pneumonia: An emerging entity. <i>Respirology</i> , 2016, 21, 65-75.	1.3	31
315	An overview of guidelines for the management of hospital-acquired and ventilator-associated pneumonia caused by multidrug-resistant Gram-negative bacteria. <i>Current Opinion in Infectious Diseases</i> , 2019, 32, 656-662.	1.3	31
316	Prevalence and risk factors for <i>Enterobacteriaceae</i> in patients hospitalized with community-acquired pneumonia. <i>Respirology</i> , 2020, 25, 543-551.	1.3	31
317	A multicentre analysis of <i>Nocardia pneumonia</i> in Spain: 2010-2016. <i>International Journal of Infectious Diseases</i> , 2020, 90, 161-166.	1.5	31
318	The Evolution and Distribution of Pneumococcal Serotypes in Adults Hospitalized With Community-Acquired Pneumonia in Spain Using a Serotype-Specific Urinary Antigen Detection Test: The CAPA Study, 2011-2018. <i>Clinical Infectious Diseases</i> , 2021, 73, 1075-1085.	2.9	31
319	Downregulation of DBC1 expression in acute lymphoblastic leukaemia is mediated by aberrant methylation of its promoter. <i>British Journal of Haematology</i> , 2006, 134, 137-144.	1.2	30
320	IgM levels in plasma predict outcome in severe pandemic influenza. <i>Journal of Clinical Virology</i> , 2013, 58, 564-567.	1.6	30
321	Importance of <i>Legionella pneumophila</i> in the Etiology of Severe Community-Acquired Pneumonia in Santiago, Chile. <i>Chest</i> , 2014, 145, 290-296.	0.4	30
322	Improvement of antibiotic therapy and ICU survival in severe non-pneumococcal community-acquired pneumonia: a matched case-control study. <i>Critical Care</i> , 2015, 19, 335.	2.5	30
323	Factors associated with hospitalization in bronchiectasis exacerbations: a one-year follow-up study. <i>Respiratory Research</i> , 2017, 18, 176.	1.4	30
324	A Phase 3, Randomized, Double-Blind, Multicenter Study To Evaluate the Safety and Efficacy of Intravenous Iclaprim versus Vancomycin for Treatment of Acute Bacterial Skin and Skin Structure Infections Suspected or Confirmed To Be Due to Gram-Positive Pathogens (REVIVE-2 Study). <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	30

#	ARTICLE	IF	CITATIONS
325	Pure Viral Sepsis Secondary to Community-Acquired Pneumonia in Adults: Risk and Prognostic Factors. <i>Journal of Infectious Diseases</i> , 2019, 220, 1166-1171.	1.9	30
326	Can Artificial Intelligence Improve the Management of Pneumonia. <i>Journal of Clinical Medicine</i> , 2020, 9, 248.	1.0	30
327	Methylation status of Wnt signaling pathway genes affects the clinical outcome of Philadelphia <sup>+</sup> acute lymphoblastic leukemia. <i>Cancer Science</i> , 2008, 99, 1865-1868.	1.7	29
328	Outcomes in patients with community-acquired pneumonia admitted to the intensive care unit. <i>Respiratory Medicine</i> , 2015, 109, 743-750.	1.3	29
329	Impact of amoxicillin therapy on resistance selection in patients with community-acquired lower respiratory tract infections: a randomized, placebo-controlled study. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 3258-3267.	1.3	29
330	Serum levels of immunoglobulins and severity of community-acquired pneumonia. <i>BMJ Open Respiratory Research</i> , 2016, 3, e000152.	1.2	29
331	Characteristics and Management of Community-Acquired Pneumonia in the Era of Global Aging. <i>Medical Sciences (Basel, Switzerland)</i> , 2018, 6, 35.	1.3	29
332	Severe community-acquired pneumonia. <i>Current Opinion in Critical Care</i> , 2004, 10, 369-374.	1.6	28
333	Experimental <i>Pseudomonas aeruginosa</i> pneumonia: evaluation of the associated inflammatory response. <i>European Respiratory Journal</i> , 2007, 30, 1167-1172.	3.1	28
334	Direct analysis of bacterial viability in endotracheal tube biofilm from a pig model of methicillin-resistant <i>Staphylococcus aureus</i> pneumonia following antimicrobial therapy. <i>FEMS Immunology and Medical Microbiology</i> , 2012, 65, 309-317.	2.7	28
335	Lung ultrasound in the evaluation of pleural effusion. <i>Jornal Brasileiro De Pneumologia</i> , 2014, 40, 1-5.	0.4	28
336	Gravity Predominates Over Ventilatory Pattern in the Prevention of Ventilator-Associated Pneumonia. <i>Critical Care Medicine</i> , 2014, 42, e620-e627.	0.4	28
337	Age-related risk factors for bacterial aetiology in community-acquired pneumonia. <i>Respirology</i> , 2016, 21, 1472-1479.	1.3	28
338	Clinical variables predicting the risk of a hospital stay for longer than 7% days in patients with severe acute exacerbations of chronic obstructive pulmonary disease: a prospective study. <i>Respiratory Research</i> , 2018, 19, 261.	1.4	28
339	SARS-CoV-2-induced Acute Respiratory Distress Syndrome: Pulmonary Mechanics and Gas-Exchange Abnormalities. <i>Annals of the American Thoracic Society</i> , 2020, 17, 1164-1168.	1.5	28
340	Time to blood culture positivity as a predictor of clinical outcomes and severity in adults with bacteremic pneumococcal pneumonia. <i>PLoS ONE</i> , 2017, 12, e0182436.	1.1	28
341	Label-Free Plasmonic Biosensor for Rapid, Quantitative, and Highly Sensitive COVID-19 Serology: Implementation and Clinical Validation. <i>Analytical Chemistry</i> , 2022, 94, 975-984.	3.2	28
342	Pulmonary infections in non-HIV-immunocompromised patients. <i>Current Opinion in Pulmonary Medicine</i> , 2005, 11, 213-217.	1.2	27

#	ARTICLE	IF	CITATIONS
343	Clinical outcomes of HIV-infected patients hospitalized with bacterial community-acquired pneumonia. <i>International Journal of Infectious Diseases</i> , 2010, 14, e22-e27.	1.5	27
344	Risk factors for multidrug-resistant pathogens in bronchiectasis exacerbations. <i>BMC Infectious Diseases</i> , 2017, 17, 659.	1.3	27
345	Twenty-year trend in mortality among hospitalized patients with pneumococcal community-acquired pneumonia. <i>PLoS ONE</i> , 2018, 13, e0200504.	1.1	27
346	Serum levels of hyaluronic acid are associated with COPD severity and predict survival. <i>European Respiratory Journal</i> , 2019, 53, 1801183.	3.1	27
347	Lymphocytopenia as a Predictor of Mortality in Patients with ICU-Acquired Pneumonia. <i>Journal of Clinical Medicine</i> , 2019, 8, 843.	1.0	27
348	Management of pneumonia in critically ill patients. <i>BMJ, The</i> , 2021, 375, e065871.	3.0	27
349	Effect of cyclosporin on plasma lipoproteins in bone marrow transplantation patients. <i>Clinical Biochemistry</i> , 1992, 25, 379-386.	0.8	26
350	Dying from pneumonia: What gene is the culprit?*. <i>Critical Care Medicine</i> , 2004, 32, 1225-1226.	0.4	26
351	Influence of antipseudomonal agents on <i>Pseudomonas aeruginosa</i> colonization and acquisition of resistance in critically ill medical patients. <i>Intensive Care Medicine</i> , 2009, 35, 439-447.	3.9	26
352	Piperacillin population pharmacokinetics in critically ill patients with multiple organ dysfunction syndrome receiving continuous venovenous haemodiafiltration: effect of type of dialysis membrane on dosing requirements. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1651-1659.	1.3	26
353	An international perspective on hospitalized patients with viral community-acquired pneumonia. <i>European Journal of Internal Medicine</i> , 2019, 60, 54-70.	1.0	26
354	International Perspective on the New 2019 American Thoracic Society/Infectious Diseases Society of America Community-Acquired Pneumonia Guideline. <i>Chest</i> , 2020, 158, 1912-1918.	0.4	26
355	Community-acquired pneumonia severity assessment tools in patients hospitalized with COVID-19: a validation and clinical applicability study. <i>Clinical Microbiology and Infection</i> , 2021, 27, 1037.e1-1037.e8.	2.8	26
356	Diagnostic Value of Telescoping Plugged Catheters in HIV-Infected Patients with Pulmonary Infiltrates. <i>Chest</i> , 1992, 102, 76-83.	0.4	25
357	Respiratory nosocomial infections in the medical intensive care unit. <i>Microbes and Infection</i> , 2005, 7, 292-301.	1.0	25
358	A review of guidelines for antibacterial use in acute exacerbations of chronic bronchitis. <i>Pulmonary Pharmacology and Therapeutics</i> , 2006, 19, 361-369.	1.1	25
359	Linezolid limits burden of methicillin-resistant <i>Staphylococcus aureus</i> in biofilm of tracheal tubes. <i>Critical Care Medicine</i> , 2012, 40, 2385-2389.	0.4	25
360	The clinical positioning of telavancin in Europe. <i>International Journal of Antimicrobial Agents</i> , 2015, 45, 213-220.	1.1	25

#	ARTICLE	IF	CITATIONS
361	Clinical management of community acquired pneumonia in the elderly patient. <i>Expert Review of Respiratory Medicine</i> , 2016, 10, 1211-1220.	1.0	25
362	Pneumonia presenting with organ dysfunctions: Causative microorganisms, host factors and outcome. <i>Journal of Infection</i> , 2016, 73, 419-426.	1.7	25
363	Severe flu management: a point of view. <i>Intensive Care Medicine</i> , 2020, 46, 153-162.	3.9	25
364	Q Fever ( <i>Coxiella Burnetii</i> ). <i>Seminars in Respiratory and Critical Care Medicine</i> , 2020, 41, 509-521.	0.8	25
365	Treatment with macrolides and glucocorticosteroids in severe community-acquired pneumonia: A post-hoc exploratory analysis of a randomized controlled trial. <i>PLoS ONE</i> , 2017, 12, e0178022.	1.1	25
366	Predictors of treatment failure and clinical stability in patients with community acquired pneumonia. <i>Annals of Translational Medicine</i> , 2017, 5, 443-443.	0.7	25
367	INVASIVE DIAGNOSTIC TECHNIQUES FOR PNEUMONIA: PROTECTED SPECIMEN BRUSH, BRONCHOALVEOLAR LAVAGE, AND LUNG BIOPSY METHODS. <i>Infectious Disease Clinics of North America</i> , 1998, 12, 701-722.	1.9	24
368	Capnometric Recirculation Gas Tonometry and Weaning from Mechanical Ventilation. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2000, 161, 171-176.	2.5	24
369	Normativa SEPAR: neumonía nosocomial. <i>Archivos De Bronconeumología</i> , 2011, 47, 510-520.	0.4	24
370	Passive smoking at home is a risk factor for community-acquired pneumonia in older adults: a population-based case-control study. <i>BMJ Open</i> , 2014, 4, e005133-e005133.	0.8	24
371	Predicting treatment failure in patients with community acquired pneumonia: a case-control study. <i>Respiratory Research</i> , 2014, 15, 75.	1.4	24
372	Discontinuing noninvasive ventilation in severe chronic obstructive pulmonary disease exacerbations: a randomised controlled trial. <i>European Respiratory Journal</i> , 2017, 50, 1601448.	3.1	24
373	Elaboration of Consensus Clinical Endpoints to Evaluate Antimicrobial Treatment Efficacy in Future Hospital-acquired/Ventilator-associated Bacterial Pneumonia Clinical Trials. <i>Clinical Infectious Diseases</i> , 2019, 69, 1912-1918.	2.9	24
374	Invasive and non-invasive diagnostic approaches for microbiological diagnosis of hospital-acquired pneumonia. <i>Critical Care</i> , 2019, 23, 51.	2.5	24
375	Reconsidering ventilator-associated pneumonia from a new dimension of the lung microbiome. <i>EBioMedicine</i> , 2020, 60, 102995.	2.7	24
376	Aspiration Risk Factors, Microbiology, and Empiric Antibiotics for Patients Hospitalized With Community-Acquired Pneumonia. <i>Chest</i> , 2021, 159, 58-72.	0.4	24
377	Corticosteroids for CAP, influenza and COVID-19: when, how and benefits or harm?. <i>European Respiratory Review</i> , 2021, 30, 200346.	3.0	24
378	Aspiration pneumonia: A renewed perspective and practical approach. <i>Respiratory Medicine</i> , 2021, 185, 106485.	1.3	24

#	ARTICLE	IF	CITATIONS
379	Reduction of thrombotic and hemorrhagic complications after stent implantation. American Heart Journal, 1996, 132, 1119-1126.	1.2	23
380	Prevention and management of ventilator-associated pneumonia. Current Opinion in Critical Care, 2002, 8, 58-69.	1.6	23
381	HLA-DPB1 MISMATCH IN HLA-A-B-DRB1 IDENTICAL SIBLING DONOR STEM CELL TRANSPLANTATION AND ACUTE GRAFT-VERSUS-HOST DISEASE. Transplantation, 2004, 77, 1107-1110.	0.5	23
382	Endotracheal Tubes for Critically Ill Patients. Chest, 2015, 147, 1327-1335.	0.4	23
383	C-Reactive Protein at Discharge, Diabetes Mellitus and 1 Hospitalization During Previous Year Predict Early Readmission in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2015, 12, 311-320.	0.7	23
384	New aspects in the management of pneumonia. Critical Care, 2016, 20, 267.	2.5	23
385	Biomarkers kinetics in the assessment of ventilator-associated pneumonia response to antibiotics - results from the BioVAP study. Journal of Critical Care, 2017, 41, 91-97.	1.0	23
386	The burden of PCV13 serotypes in hospitalized pneumococcal pneumonia in Spain using a novel urinary antigen detection test. CAPA study. Vaccine, 2017, 35, 5264-5270.	1.7	23
387	Is ventilated hospital-acquired pneumonia a worse entity than ventilator-associated pneumonia?. European Respiratory Review, 2020, 29, 200023.	3.0	23
388	Assessment of a Loop-Mediated Isothermal Amplification (LAMP) Assay for the Rapid Detection of Pathogenic Bacteria from Respiratory Samples in Patients with Hospital-Acquired Pneumonia. Microorganisms, 2020, 8, 103.	1.6	23
389	The evolution of the ventilatory ratio is a prognostic factor in mechanically ventilated COVID-19 ARDS patients. Critical Care, 2021, 25, 331.	2.5	23
390	Higher frequency of comorbidities in fully vaccinated patients admitted to the ICU due to severe COVID-19: a prospective, multicentre, observational study. European Respiratory Journal, 2022, 59, 2102275.	3.1	23
391	Antibiotic Treatment Against Methicillin-Resistant Staphylococcus aureus Hospital- and Ventilator-acquired Pneumonia: A Step Forward but the Battle Continues. Clinical Infectious Diseases, 2012, 54, 630-632.	2.9	22
392	Risk factors of postoperative nosocomial pneumonia after resection of bronchogenic carcinoma. Respiratory Medicine, 2012, 106, 1463-1471.	1.3	22
393	ICU-Acquired Pneumonia With or Without Etiologic Diagnosis. Critical Care Medicine, 2013, 41, 2133-2143.	0.4	22
394	Year in review in Intensive Care Medicine 2013: I. Acute kidney injury, ultrasound, hemodynamics, cardiac arrest, transfusion, neurocritical care, and nutrition. Intensive Care Medicine, 2014, 40, 147-159.	3.9	22
395	The management of severe community acquired pneumonia in the intensive care unit. Expert Review of Respiratory Medicine, 2014, 8, 293-303.	1.0	22
396	Year in review in Intensive Care Medicine 2014: III. Severe infections, septic shock, healthcare-associated infections, highly resistant bacteria, invasive fungal infections, severe viral infections, Ebola virus disease and paediatrics. Intensive Care Medicine, 2015, 41, 575-588.	3.9	22

#	ARTICLE	IF	CITATIONS
397	Endotracheal tube biofilm translocation in the lateral Trendelenburg position. <i>Critical Care</i> , 2015, 19, 59.	2.5	22
398	Predicting In-Hospital Treatment Failure (≥7 days) in Patients with COPD Exacerbation Using Antibiotics and Systemic Steroids. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2016, 13, 82-92.	0.7	22
399	Intensive care unit patients with lower respiratory tract nosocomial infections: the ENIRRI project. <i>ERJ Open Research</i> , 2017, 3, 00092-2017.	1.1	22
400	Immunological profiling to assess disease severity and prognosis in community-acquired pneumonia. <i>Lancet Respiratory Medicine</i> , 2017, 5, e35-e36.	5.2	22
401	Clinical impact of chronic obstructive pulmonary disease on non-cystic fibrosis bronchiectasis. A study on 1,790 patients from the Spanish Bronchiectasis Historical Registry. <i>PLoS ONE</i> , 2017, 12, e0177931.	1.1	22
402	Risk and Prognostic Factors in Very Old Patients with Sepsis Secondary to Community-Acquired Pneumonia. <i>Journal of Clinical Medicine</i> , 2019, 8, 961.	1.0	22
403	Evaluation of nonresolving and progressive pneumonia. <i>Seminars in Respiratory Infections</i> , 2003, 18, 103-11.	1.3	22
404	Protein C, protein S and C4b-binding protein in neonatal severe infection and septic shock. <i>Journal of Perinatal Medicine</i> , 1992, 20, 111-116.	0.6	21
405	Effect of Acetylsalicylic Acid on Pulmonary Gas Exchange in Patients With Severe Pneumonia. <i>Chest</i> , 1997, 111, 1094-1100.	0.4	21
406	Serum immunoglobulins in the infected and convalescent phases in community-acquired pneumonia. <i>Respiratory Medicine</i> , 2013, 107, 2038-2045.	1.3	21
407	Community-acquired pneumonia in adults: Highlighting missed opportunities for vaccination. <i>European Journal of Internal Medicine</i> , 2017, 37, 13-18.	1.0	21
408	Inhaled amikacin for severe Gram-negative pulmonary infections in the intensive care unit: current status and future prospects. <i>Critical Care</i> , 2018, 22, 343.	2.5	21
409	Microorganisms resistant to conventional antimicrobials in acute exacerbations of chronic obstructive pulmonary disease. <i>Respiratory Research</i> , 2018, 19, 119.	1.4	21
410	Impact of bronchiectasis on outcomes of hospitalized patients with acute exacerbation of chronic obstructive pulmonary disease: A propensity matched analysis. <i>Scientific Reports</i> , 2018, 8, 9236.	1.6	21
411	One Year Overview and Follow-Up in a Post-COVID Consultation of Critically Ill Patients. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	21
412	Inflammatory Responses in Blood Samples of Human Immunodeficiency Virus-Infected Patients with Pulmonary Infections. <i>Vaccine Journal</i> , 2004, 11, 608-614.	3.2	20
413	Does ventilator-associated tracheobronchitis need antibiotic treatment?. <i>Critical Care</i> , 2005, 9, 255.	2.5	20
414	Valganciclovir as Pre-Emptive Therapy for Cytomegalovirus Infection in Allogeneic Haematopoietic Stem Cell Transplant Recipients. <i>Antiviral Therapy</i> , 2011, 16, 951-957.	0.6	20



#	ARTICLE	IF	CITATIONS
415	Levofloxacin for the treatment of respiratory tract infections. Expert Opinion on Pharmacotherapy, 2012, 13, 1203-1212.	0.9	20
416	Impact of chronic liver disease in intensive care unit acquired pneumonia: a prospective study. Intensive Care Medicine, 2013, 39, 1776-1784.	3.9	20
417	Inhaled corticosteroids and systemic inflammatory response in community-acquired pneumonia: A prospective clinical study. Respirology, 2014, 19, 929-935.	1.3	20
418	Exertional Hypoxemia in Stable COPD Is Common and Predicted by Circulating Proadrenomedullin. Chest, 2014, 146, 328-338.	0.4	20
419	Microbiology and outcomes of community acquired pneumonia in non cystic-fibrosis bronchiectasis patients. Journal of Infection, 2015, 71, 28-36.	1.7	20
420	Antimicrobial Resistance Among Streptococcus pneumoniae. , 2018, , 13-38.		20
421	Antivirals for influenza-Like Illness? A randomised Controlled trial of Clinical and Cost effectiveness in primary CarE (ALIC <sup>4</sup> ): the ALIC <sup>4</sup> protocol. BMJ Open, 2018, 8, e021032.	0.8	20
422	Lymphopenia Is Associated With Poor Outcomes of Patients With Community-Acquired Pneumonia and Sepsis. Open Forum Infectious Diseases, 2021, 8, ofab169.	0.4	20
423	New guidelines for severe community-acquired pneumonia. Current Opinion in Pulmonary Medicine, 2021, 27, 210-215.	1.2	20
424	Pulmonary Infiltrates in HIV-Infected Patients in the Highly Active Antiretroviral Therapy Era in Spain. Journal of Acquired Immune Deficiency Syndromes (1999), 2001, 27, 35-43.	0.9	19
425	Current Perspective of the HCAP Problem: Is It CAP or Is It HAP?. Seminars in Respiratory and Critical Care Medicine, 2009, 30, 239-248.	0.8	19
426	Year in review in Intensive Care Medicine 2013: II. Sedation, invasive and noninvasive ventilation, airways, ARDS, ECMO, family satisfaction, end-of-life care, organ donation, informed consent, safety, hematological issues in critically ill patients. Intensive Care Medicine, 2014, 40, 305-319.	3.9	19
427	The SAATELLITE and EVADE Clinical Studies Within the COMBACTE Consortium: A Public-Private Collaborative Effort in Designing and Performing Clinical Trials for Novel Antibacterial Drugs to Prevent Nosocomial Pneumonia: Table 1.. Clinical Infectious Diseases, 2016, 63, S46-S51.	2.9	19
428	Assessment of in vivo versus in vitro biofilm formation of clinical methicillin-resistant Staphylococcus aureus isolates from endotracheal tubes. Scientific Reports, 2018, 8, 11906.	1.6	19
429	PES Pathogens in Severe Community-Acquired Pneumonia. Microorganisms, 2019, 7, 49.	1.6	19
430	Pulmonary gas exchange response to weaning with pressure-support ventilation in exacerbated chronic obstructive pulmonary disease patients. Intensive Care Medicine, 2002, 28, 1595-1599.	3.9	18
431	Respiratory Microbiology Patterns Within the First 24 h of ARDS Diagnosis. Chest, 2005, 128, 273-279.	0.4	18
432	Diagnostic Strategies for Healthcare-Associated Pneumonia. Seminars in Respiratory and Critical Care Medicine, 2009, 30, 036-045.	0.8	18

#	ARTICLE	IF	CITATIONS
433	OUTCOME OF ANTIFUNGAL COMBINATION THERAPY FOR INVASIVE MOLD INFECTIONS IN HEMATOLOGICAL PATIENTS IS INDEPENDENT OF THE CHOSEN COMBINATION. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2012, 4, e2012011.	0.5	18
434	Mannose-binding lectin protein and its association to clinical outcomes in COPD: a longitudinal study. <i>Respiratory Research</i> , 2015, 16, 150.	1.4	18
435	Ceftobiprole for the treatment of pneumonia: a&nbsp;European perspective. <i>Drug Design, Development and Therapy</i> , 2015, 9, 4565.	2.0	18
436	A Phase II Randomized, Double-blind, Multicenter Study to Evaluate Efficacy and Safety of Intravenous Iclaprim Versus Vancomycin for the Treatment of Nosocomial Pneumonia Suspected or Confirmed to be Due to Gram-positive Pathogens. <i>Clinical Therapeutics</i> , 2017, 39, 1706-1718.	1.1	18
437	Bacterial etiology of community-acquired pneumonia in immunocompetent hospitalized patients and appropriateness of empirical treatment recommendations: an international point-prevalence study. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2020, 39, 1513-1525.	1.3	18
438	Validation of a Prediction Score for Drug-Resistant Microorganisms in Community-acquired Pneumonia. <i>Annals of the American Thoracic Society</i> , 2021, 18, 257-265.	1.5	18
439	Tracheostomy Timing and Outcome in Severe COVID-19: The WeanTrach Multicenter Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 2651.	1.0	18
440	Tissue Factor (TF) and Urokinase Plasminogen Activator Receptor (uPAR) and Bleeding Complications in Leukemic Patients. <i>Thrombosis and Haemostasis</i> , 1997, 77, 062-070.	1.8	18
441	One-year mortality after ICU admission due to COVID-19 infection. <i>Intensive Care Medicine</i> , 2022, 48, 366-368.	3.9	18
442	Ventilator-associated pneumoniaâ€”Understanding epidemiology and pathogenesis to guide prevention and empiric therapy. <i>Clinical Microbiology and Infection</i> , 1997, 3, S61-S76.	2.8	17
443	FLEXIBLE BRONCHOSCOPY IN NOSOCOMIAL PNEUMONIA. <i>Clinics in Chest Medicine</i> , 2001, 22, 263-279.	0.8	17
444	Signal Transduction Pathways Underlying the Expression of Tissue Factor and Thrombomodulin in Promyelocytic Cells Induced to Differentiate by Retinoid Acid and Dibutyryl cAMP. <i>Thrombosis and Haemostasis</i> , 2001, 85, 1031-1036.	1.8	17
445	Optimizing Treatment Outcomes in Severe Community-Acquired Pneumonia. <i>Treatments in Respiratory Medicine</i> , 2003, 2, 39-54.	1.4	17
446	Voriconazole as primary antifungal prophylaxis in patients with neutropenia after hematopoietic stem cell transplantation or chemotherapy for acute myeloid leukemia. <i>European Journal of Haematology</i> , 2010, 84, 271-273.	1.1	17
447	A European survey of nosocomial infection control and hospital-acquired pneumonia prevention practices. <i>Journal of Infection</i> , 2012, 65, 285-291.	1.7	17
448	Telavancin versus vancomycin for bacteraemic hospital-acquired pneumonia. <i>International Journal of Antimicrobial Agents</i> , 2013, 42, 367-369.	1.1	17
449	From starting mechanical ventilation to ventilator-associated pneumonia, choosing the right moment to start antibiotic treatment. <i>Critical Care</i> , 2016, 20, 169.	2.5	17
450	Sepsis and community-acquired pneumonia. <i>Annals of Research Hospitals</i> , 0, 2, 7-7.	0.0	17

#	ARTICLE	IF	CITATIONS
451	Pneumonic and non-pneumonic exacerbations in bronchiectasis: Clinical and microbiological differences. <i>Journal of Infection</i> , 2018, 77, 99-106.	1.7	17
452	Neuraminidase Inhibitors and Hospital Length of Stay: A Meta-analysis of Individual Participant Data to Determine Treatment Effectiveness Among Patients Hospitalized With Nonfatal 2009 Pandemic Influenza A(H1N1) Virus Infection. <i>Journal of Infectious Diseases</i> , 2020, 221, 356-366.	1.9	17
453	Comparative efficacy of linezolid and vancomycin for endotracheal tube MRSA biofilms from ICU patients. <i>Critical Care</i> , 2019, 23, 251.	2.5	17
454	Systemic Inflammation during and after Bronchiectasis Exacerbations: Impact of <i>Pseudomonas aeruginosa</i> . <i>Journal of Clinical Medicine</i> , 2020, 9, 2631.	1.0	17
455	Understanding the Host in the Management of Pneumonia. An Official American Thoracic Society Workshop Report. <i>Annals of the American Thoracic Society</i> , 2021, 18, 1087-1097.	1.5	17
456	Major candidate variables to guide personalised treatment with steroids in critically ill patients with COVID-19: CIBERESUCICOVID study. <i>Intensive Care Medicine</i> , 2022, 48, 850-864.	3.9	17
457	Regenerative Therapy in Patients With a Revascularized Acute Anterior Myocardial Infarction and Depressed Ventricular Function. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2007, 60, 357-365.	0.4	16
458	Experimental safety and efficacy evaluation of an extracorporeal pumpless artificial lung in providing respiratory support through the axillary vessels. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2007, 133, 339-345.e2.	0.4	16
459	Punción transbronquial aspirativa en el estudio de las adenopatías mediastínicas: rentabilidad y coste-beneficio. <i>Archivos De Bronconeumología</i> , 2008, 44, 290-294.	0.4	16
460	Surveillance of iclaprim activity: In vitro susceptibility of gram-positive pathogens collected from 2012 to 2014 from the United States, Asia Pacific, Latin American and Europe. <i>Diagnostic Microbiology and Infectious Disease</i> , 2018, 90, 329-334.	0.8	16
461	The value of serology testing to manage SARS-CoV-2 infections. <i>European Respiratory Journal</i> , 2020, 56, 2002411.	3.1	16
462	Molecular characterization of methicillin-resistant <i>Staphylococcus aureus</i> clinical strains from the endotracheal tubes of patients with nosocomial pneumonia. <i>Antimicrobial Resistance and Infection Control</i> , 2020, 9, 43.	1.5	16
463	Association between physical activity and risk of hospitalisation in bronchiectasis. <i>European Respiratory Journal</i> , 2020, 55, 1902138.	3.1	16
464	Diagnosis of Pneumonia and Monitoring of Infection Eradication. <i>Drugs</i> , 2000, 60, 1289-1302.	4.9	15
465	Coordinated deregulation of cellular receptors, proangiogenic factors and intracellular pathways in acute myeloid leukaemia. <i>Leukemia and Lymphoma</i> , 2007, 48, 1187-1199.	0.6	15
466	New therapy options for MRSA with respiratory infection/pneumonia. <i>Current Opinion in Infectious Diseases</i> , 2012, 25, 159-165.	1.3	15
467	Tumor necrosis factor receptor 1 (TNFRI) for ventilator-associated pneumonia diagnosis by cytokine multiplex analysis. <i>Intensive Care Medicine Experimental</i> , 2015, 3, 26.	0.9	15
468	Community-Acquired Pneumococcal Pneumonia in Virologically Suppressed HIV-Infected Adult Patients. <i>Chest</i> , 2017, 152, 295-303.	0.4	15

#	ARTICLE	IF	CITATIONS
469	Pooled analysis of the phase 3 REVIVE trials: randomised, double-blind studies to evaluate the safety and efficacy of iclaprim versus vancomycin for treatment of acute bacterial skin and skin-structure infections. <i>International Journal of Antimicrobial Agents</i> , 2018, 52, 233-240.	1.1	15
470	Community-acquired bacterial pneumonia in adult HIV-infected patients. <i>Expert Review of Anti-Infective Therapy</i> , 2018, 16, 579-588.	2.0	15
471	The association of cardiovascular failure with treatment for ventilator-associated lower respiratory tract infection. <i>Intensive Care Medicine</i> , 2019, 45, 1753-1762.	3.9	15
472	Nebulized Amikacin and Fosfomycin for Severe <i>Pseudomonas aeruginosa</i> Pneumonia. <i>Critical Care Medicine</i> , 2019, 47, e470-e477.	0.4	15
473	A Phase 2 Study of Pimodivir (JNJ-63623872) in Combination With Oseltamivir in Elderly and Nonelderly Adults Hospitalized With Influenza A Infection: OPAL Study. <i>Journal of Infectious Diseases</i> , 2022, 226, 109-118.	1.9	15
474	Clinical and Microbiological Outcomes of Ceftazidime-Avibactam Treatment in Adults with Gram-Negative Bacteremia: A Subset Analysis from the Phase 3 Clinical Trial Program. <i>Infectious Diseases and Therapy</i> , 2021, 10, 2399-2414.	1.8	15
475	Identification of circulating microRNA profiles associated with pulmonary function and radiologic features in survivors of SARS-CoV-2-induced ARDS. <i>Emerging Microbes and Infections</i> , 2022, 11, 1537-1549.	3.0	15
476	The new American Thoracic Society/Infectious Disease Society of North America guidelines for the management of hospital-acquired, ventilator-associated and healthcare-associated pneumonia: a current view and new complementary information. <i>Current Opinion in Critical Care</i> , 2006, 12, 444-445.	1.6	14
477	Severity and outcomes of community acquired pneumonia in asthmatic patients. <i>Respiratory Medicine</i> , 2014, 108, 1713-1722.	1.3	14
478	Impact of COPD in the Outcome of ICU-Acquired Pneumonia With and Without Previous Intubation. <i>Chest</i> , 2015, 147, 1530-1538.	0.4	14
479	New antimicrobial approaches to gram positive respiratory infections. <i>Pulmonary Pharmacology and Therapeutics</i> , 2015, 32, 137-143.	1.1	14
480	Readmission in COPD patients: should we consider it a marker of quality of care or a marker of a more severe disease with a worse prognosis?. <i>European Respiratory Journal</i> , 2016, 48, 279-281.	3.1	14
481	Drugs that increase the risk of community-acquired pneumonia: a narrative review. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 991-1003.	1.0	14
482	Molecular analysis of lineage-specific chimerism and minimal residual disease by RT-PCR of p210BCR-ABL and p190BCR-ABL after allogeneic bone marrow transplantation for chronic myeloid leukemia: increasing mixed myeloid chimerism and p190BCR-ABL detection precede cytogenetic relapse. <i>Blood</i> , 2000, 95, 2659-2665.	0.6	14
483	Additive effect of PTK787/ZK 222584, a potent inhibitor of VEGFR phosphorylation, with Idarubicin in the treatment of acute myeloid leukemia. <i>Experimental Hematology</i> , 2009, 37, 679-691.	0.2	13
484	Do guidelines change outcomes in ventilator-associated pneumonia?. <i>Current Opinion in Infectious Diseases</i> , 2010, 23, 171-177.	1.3	13
485	Incidental Chest Radiographic Findings in Adult Patients With Acute Cough. <i>Annals of Family Medicine</i> , 2012, 10, 510-515.	0.9	13
486	Upper Respiratory Symptoms Worsen over Time and Relate to Clinical Phenotype in Chronic Obstructive Pulmonary Disease. <i>Annals of the American Thoracic Society</i> , 2015, 12, 997-1004.	1.5	13

#	ARTICLE	IF	CITATIONS
487	Multilobar bilateral and unilateral chest radiograph involvement: implications for prognosis in hospitalised community-acquired pneumonia. <i>European Respiratory Journal</i> , 2016, 48, 257-261.	3.1	13
488	Invasive Disease vs Urinary Antigen-Confirmed Pneumococcal Community-Acquired Pneumonia. <i>Chest</i> , 2017, 151, 1311-1319.	0.4	13
489	Ventilator-Associated Pneumonia and PaO <sub>2</sub> /FIO <sub>2</sub> Diagnostic Accuracy: Changing the Paradigm?. <i>Journal of Clinical Medicine</i> , 2019, 8, 1217.	1.0	13
490	Short-Term Appraisal of the Effects and Safety of Manual Versus Ventilator Hyperinflation in an Animal Model of Severe Pneumonia. <i>Respiratory Care</i> , 2019, 64, 760-770.	0.8	13
491	The Value of C-Reactive Protein-to-Lymphocyte Ratio in Predicting the Severity of SARS-CoV-2 Pneumonia. <i>Archivos De Bronconeumologia</i> , 2021, 57, 79-82.	0.4	13
492	Early oseltamivir treatment improves survival in critically ill patients with influenza pneumonia. <i>ERJ Open Research</i> , 2021, 7, 00888-2020.	1.1	13
493	Nebulized antibiotics for ventilator-associated pneumonia: methodological framework for future multicenter randomized controlled trials. <i>Current Opinion in Infectious Diseases</i> , 2021, 34, 156-168.	1.3	13
494	Severe Community-Acquired Pneumonia. <i>Seminars in Respiratory and Critical Care Medicine</i> , 1996, 17, 265-271.	0.8	12
495	Treatment failures in patients with ventilator-associated pneumonia. <i>Infectious Disease Clinics of North America</i> , 2003, 17, 753-771.	1.9	12
496	Antibacterial dosage in intensive-care-unit patients based on pharmacokinetic/pharmacodynamic principles. <i>Current Opinion in Critical Care</i> , 2006, 12, 477-482.	1.6	12
497	Influence of bacterial resistances on the efficiency of antibiotic treatments for community-acquired pneumonia. <i>European Journal of Health Economics</i> , 2008, 9, 23-32.	1.4	12
498	Changes in management of chronic obstructive pulmonary disease (COPD) in primary care: EMMEPOC study. <i>Respiratory Medicine</i> , 2010, 104, 67-75.	1.3	12
499	The Impact of Guidelines on the Outcomes of Community-acquired and Ventilator-associated Pneumonia. <i>Clinics in Chest Medicine</i> , 2011, 32, 491-505.	0.8	12
500	Noninvasive Ventilation in Withdrawal from Mechanical Ventilation. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2014, 35, 507-518.	0.8	12
501	Hospitalized patients at risk of dying: an Intensive Care Medicine call for papers. <i>Intensive Care Medicine</i> , 2016, 42, 1-2.	3.9	12
502	Emerging drugs for nosocomial pneumonia. <i>Expert Opinion on Emerging Drugs</i> , 2016, 21, 331-341.	1.0	12
503	Body Position and Ventilator-Associated Pneumonia Prevention. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2017, 38, 371-380.	0.8	12
504	IFN $\beta$ 3/4 locus polymorphisms and IFN $\beta$ 3 circulating levels are associated with COPD severity and outcomes. <i>BMC Pulmonary Medicine</i> , 2018, 18, 51.	0.8	12

#	ARTICLE	IF	CITATIONS
505	Adjuvant therapies in critical care: steroids in community-acquired pneumonia. <i>Intensive Care Medicine</i> , 2018, 44, 478-481.	3.9	12
506	Invasive Pulmonary Aspergillosis in Ventilator-associated Pneumonia: The Hidden Enemy?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 202, 1071-1073.	2.5	12
507	Advances in molecular diagnostic tests for pneumonia. <i>Current Opinion in Pulmonary Medicine</i> , 2020, 26, 241-248.	1.2	12
508	ICU-Acquired Pneumonia Is Associated with Poor Health Post-COVID-19 Syndrome. <i>Journal of Clinical Medicine</i> , 2022, 11, 224.	1.0	12
509	Severe community-acquired pneumonia. <i>Current Opinion in Critical Care</i> , 2002, 8, 453-460.	1.6	11
510	Pneumonia in the Elderly. <i>Clinical Pulmonary Medicine</i> , 2004, 11, 210-218.	0.3	11
511	Monotherapy in Severe Community-Acquired Pneumonia. <i>Chest</i> , 2005, 128, 10-13.	0.4	11
512	Effects of Stem-Cell Mobilization With Recombinant Human Granulocyte Colony Stimulating Factor in Patients With Percutaneously Revascularized Acute Anterior Myocardial Infarction. <i>Revista Española De Cardiología (English Ed )</i> , 2005, 58, 253-261.	0.4	11
513	Nosocomial pneumonia. <i>Current Opinion in Infectious Diseases</i> , 2006, 19, 327-338.	1.3	11
514	Associated inflammatory response in pneumonia: role of adjunctive therapy with glucocorticoids. <i>Current Opinion in Infectious Diseases</i> , 2006, 19, 179-184.	1.3	11
515	Viral-reactivated pneumonia during mechanical ventilation: is there need for antiviral treatment?. <i>Frontiers in Pharmacology</i> , 2011, 2, 66.	1.6	11
516	What Is the Best Approach to the Nonresponding Patient with Community-Acquired Pneumonia?. <i>Infectious Disease Clinics of North America</i> , 2013, 27, 189-203.	1.9	11
517	Managing the safety of inhaled corticosteroids in COPD and the risk of pneumonia. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 1237-1247.	1.0	11
518	Detection of human cytomegalovirus in bronchoalveolar lavage of intensive care unit patients. <i>European Respiratory Journal</i> , 2018, 51, 1701332.	3.1	11
519	Clinical Approach to Community-acquired Pneumonia. <i>Journal of Thoracic Imaging</i> , 2018, 33, 273-281.	0.8	11
520	Macrolide therapy is associated with lower mortality in community-acquired bacteraemic pneumonia. <i>Respiratory Medicine</i> , 2018, 140, 115-121.	1.3	11
521	Surveillance of iclaprim activity: in vitro susceptibility of Gram-positive skin infection pathogens collected from 2015 to 2016 from North America and Europe. <i>Diagnostic Microbiology and Infectious Disease</i> , 2019, 93, 154-158.	0.8	11
522	COVID-19 in young and middle-aged adults: predictors of poor outcome and clinical differences. <i>Infection</i> , 2022, 50, 179-189.	2.3	11

#	ARTICLE	IF	CITATIONS
523	Compliance with Guidelines-Recommended Processes in Pneumonia: Impact of Health Status and Initial Signs. PLoS ONE, 2012, 7, e37570.	1.1	11
524	Relationship between the Use of Inhaled Steroids for Chronic Respiratory Diseases and Early Outcomes in Community-Acquired Pneumonia. PLoS ONE, 2013, 8, e73271.	1.1	11
525	Statistical modeling of prognostic indices for evaluation of critically ill patients. Critical Care Medicine, 1991, 19, 867-870.	0.4	10
526	Chronic Obstructive Pulmonary Disease and Infection. Clinical Pulmonary Medicine, 1999, 6, 1-8.	0.3	10
527	Pro/con clinical debate: the use of a protected specimen brush in the diagnosis of ventilator associated pneumonia. Critical Care, 2002, 6, 117.	2.5	10
528	SEPAR Guidelines for Nosocomial Pneumonia. Archivos De Bronconeumologia, 2011, 47, 510-520.	0.4	10
529	Emerging drugs on methicillin-resistant <i>Staphylococcus aureus</i> . Expert Opinion on Emerging Drugs, 2013, 18, 291-305.	1.0	10
530	Pharmacotherapy for lower respiratory tract infections. Expert Opinion on Pharmacotherapy, 2014, 15, 2307-2318.	0.9	10
531	Inhaled Corticosteroids Do Not Influence the Early Inflammatory Response and Clinical Presentation of Hospitalized Subjects With COPD Exacerbation. Respiratory Care, 2014, 59, 1550-1559.	0.8	10
532	Professions and Working Conditions Associated With Community-Acquired Pneumonia. Archivos De Bronconeumologia, 2015, 51, 627-631.	0.4	10
533	Relaci3n de las profesiones y las condiciones laborales con la neumon3a adquirida en la comunidad. Archivos De Bronconeumologia, 2015, 51, 627-631.	0.4	10
534	Year in review in Intensive Care Medicine 2014: II. ARDS, airway management, ventilation, adjuvants in sepsis, hepatic failure, symptoms assessment and management, palliative care and support for families, prognostication, organ donation, outcome, organisation and research methodology. Intensive Care Medicine, 2015, 41, 389-401.	3.9	10
535	Nonantibiotic Adjunctive Therapies for Community-Acquired Pneumonia (Corticosteroids and Beyond): Where Are We with Them?. Seminars in Respiratory and Critical Care Medicine, 2016, 37, 913-922.	0.8	10
536	Mucoid Pseudomonas aeruginosa alters sputum viscoelasticity in patients with non-cystic fibrosis bronchiectasis. Respiratory Medicine, 2019, 154, 40-46.	1.3	10
537	Resistance mechanisms and molecular epidemiology of <i>Pseudomonas aeruginosa</i> strains from patients with bronchiectasis. Journal of Antimicrobial Chemotherapy, 2022, 77, 1600-1610.	1.3	10
538	Methodology of a Large Multicenter Observational Study of Patients with COVID-19 in Spanish Intensive Care Units. Archivos De Bronconeumologia, 2022, 58, 22-31.	0.4	10
539	Ventilator-associated pneumonia. Intensive Care Medicine, 2022, 48, 1222-1226.	3.9	10
540	Diagnostic Approaches and Hospital-Acquired Pneumonia. Seminars in Respiratory and Critical Care Medicine, 1997, 18, 149-161.	0.8	9

#	ARTICLE	IF	CITATIONS
541	Control of Epstein-Barr Virus Load and Lymphoproliferative Disease by Maintenance of CD8+T Lymphocytes in the T Lymphocyte-Depleted Graft after Bone Marrow Transplantation. <i>Journal of Infectious Diseases</i> , 2004, 190, 1596-1599.	1.9	9
542	CD4+ cell counts and HIV-RNA levels do not predict outcomes of community-acquired pneumonia in hospitalized HIV-infected patients. <i>International Journal of Infectious Diseases</i> , 2011, 15, e822-e827.	1.5	9
543	The Strange Case of Community-Acquired Pneumonia in COPD. <i>Chest</i> , 2011, 139, 483-485.	0.4	9
544	Current treatment of community-acquired pneumonia. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 1319-1332.	0.9	9
545	<i>Streptococcus pneumoniae</i> -associated pneumonia complicated by purulent pericarditis: case series. <i>Jornal Brasileiro De Pneumologia</i> , 2015, 41, 389-394.	0.4	9
546	Antibiotic therapy prior to hospital admission is associated with reduced septic shock and need for mechanical ventilation in patients with community-acquired pneumonia. <i>Journal of Infection</i> , 2017, 74, 442-449.	1.7	9
547	Community-Acquired <i>Legionella</i> Pneumonia in Human Immunodeficiency Virus-Infected Adult Patients: A Matched Case-Control Study. <i>Clinical Infectious Diseases</i> , 2018, 67, 958-961.	2.9	9
548	Early, short and long-term mortality in community-acquired pneumonia. <i>Annals of Research Hospitals</i> , 0, 2, 5-5.	0.0	9
549	Adjunctive Therapies for Community-Acquired Pneumonia. <i>Clinics in Chest Medicine</i> , 2018, 39, 753-764.	0.8	9
550	Emerging strategies for the noninvasive diagnosis of nosocomial pneumonia. <i>Expert Review of Anti-Infective Therapy</i> , 2019, 17, 523-533.	2.0	9
551	Systematic review and meta-analysis of the safety of erythromycin compared to clarithromycin in adults and adolescents with pneumonia. <i>Journal of Chemotherapy</i> , 2020, 32, 1-6.	0.7	9
552	Diagnostic accuracy of Gram staining when predicting staphylococcal hospital-acquired pneumonia and ventilator-associated pneumonia: a systematic review and meta-analysis. <i>Clinical Microbiology and Infection</i> , 2020, 26, 1456-1463.	2.8	9
553	Ceftaroline for severe community-acquired pneumonia: A real-world two-centre experience in Italy and Spain. <i>International Journal of Antimicrobial Agents</i> , 2020, 55, 105921.	1.1	9
554	Biomarkers in the ICU: less is more? No. <i>Intensive Care Medicine</i> , 2021, 47, 97-100.	3.9	9
555	Methicillin-susceptible staphylococcus aureus in community-acquired pneumonia: Risk factors and outcomes. <i>Journal of Infection</i> , 2021, 82, 76-83.	1.7	9
556	Omadacycline vs moxifloxacin in adults with community-acquired bacterial pneumonia. <i>International Journal of Infectious Diseases</i> , 2021, 104, 501-509.	1.5	9
557	Differences between sexes concerning COVID-19-related pneumonia. <i>Panminerva Medica</i> , 2022, 64, .	0.2	9
558	Severe Infections Due to Respiratory Viruses. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2022, 43, 060-074.	0.8	9



#	ARTICLE	IF	CITATIONS
559	Nosocomial pneumonia in immunosuppressed patients. <i>Infectious Disease Clinics of North America</i> , 2003, 17, 785-800.	1.9	8
560	Fungal pneumonia, chronic respiratory diseases and glucocorticoids. <i>Medical Mycology</i> , 2006, 44, 207-211.	0.3	8
561	Severity scores for CAP. 'Much workload for the next bias'. <i>Thorax</i> , 2010, 65, 853-855.	2.7	8
562	Mejor función funcional en pacientes con miocardiopatía dilatada tras la infusión intracoronaria de células mononucleares autólogas de la médula ósea. <i>Revista Espanola De Cardiologia</i> , 2013, 66, 450-457.	0.6	8
563	Effect of nitric oxide inhalation on gas exchange in acute severe pneumonia. <i>Respiratory Physiology and Neurobiology</i> , 2013, 187, 157-163.	0.7	8
564	Predictors of Readmission in a Period of 30 Days or Less in Acute Exacerbation of Chronic Obstructive Pulmonary Disease. <i>Clinical Pulmonary Medicine</i> , 2015, 22, 172-176.	0.3	8
565	The research agenda in VAP/HAP: next steps. <i>Intensive Care Medicine</i> , 2017, 43, 1389-1391.	3.9	8
566	Investigational drugs in phase I and phase II clinical trials for the treatment of community-acquired pneumonia. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 1239-1248.	1.9	8
567	The efficacy of inhaled antibiotics in non-cystic fibrosis bronchiectasis. <i>Expert Review of Respiratory Medicine</i> , 2018, 12, 683-691.	1.0	8
568	Early and late cardiovascular events in patients hospitalized for community-acquired pneumonia. <i>Archivos De Bronconeumología</i> , 2020, 56, 551-558.	0.4	8
569	Pneumonic versus Nonpneumonic Exacerbations of Chronic Obstructive Pulmonary Disease. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2020, 41, 817-829.	0.8	8
570	Cost-effectiveness Comparison of Ceftazidime/Avibactam Versus Meropenem in the Empirical Treatment of Hospital-acquired Pneumonia, Including Ventilator-associated Pneumonia, in Italy. <i>Clinical Therapeutics</i> , 2020, 42, 802-817.	1.1	8
571	Empiric antibiotics for community-acquired pneumonia in adult patients: a systematic review and a network meta-analysis. <i>Thorax</i> , 2021, 76, 1020-1031.	2.7	8
572	Nosocomial pneumonia in the intensive care unit: how should treatment failure be predicted. <i>Revista Brasileira De Terapia Intensiva</i> , 2014, 26, 208-11.	0.1	8
573	Evaluation of Nonresponding Patients with Ventilator-Associated Pneumonia. <i>Clinical Pulmonary Medicine</i> , 2001, 8, 290-295.	0.3	7
574	Approaches to suspected ventilator-associated pneumonia: relying on our own bias. <i>Intensive Care Medicine</i> , 2001, 27, 625-628.	3.9	7
575	Implementation of Guidelines on Hospital-Acquired Pneumonia. <i>Chest</i> , 2005, 128, 1900-1902.	0.4	7
576	Treatment Failure in Patients with Ventilator-Associated Pneumonia. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2006, 27, 104-114.	0.8	7

#	ARTICLE	IF	CITATIONS
577	What drives our choices? Evidence, guidelines or habit?. International Journal of Antimicrobial Agents, 2007, 29, S17-S22.	1.1	7
578	Airway Obstruction and Bronchodilator Responsiveness in Adults With Acute Cough. Annals of Family Medicine, 2012, 10, 523-529.	0.9	7
579	Systematic Implementation of Evidence-Based Guidelines in Intensive Care Medicine. Critical Care Medicine, 2013, 41, 329-331.	0.4	7
580	Year in review in Intensive Care Medicine 2013: Ill. Sepsis, infections, respiratory diseases, pediatrics. Intensive Care Medicine, 2014, 40, 471-483.	3.9	7
581	Impact of microbial ecology on accuracy of surveillance cultures to predict multidrug resistant microorganisms causing ventilator-associated pneumonia. Journal of Infection, 2014, 69, 333-340.	1.7	7
582	Bacteraemia in outpatients with community-acquired pneumonia. European Respiratory Journal, 2016, 47, 654-657.	3.1	7
583	Severity scoring systems for pneumonia. Current Opinion in Pulmonary Medicine, 2018, 24, 227-236.	1.2	7
584	Effect of Corticosteroids on C-Reactive Protein in Patients with Severe Community-Acquired Pneumonia and High Inflammatory Response: The Effect of Lymphopenia. Journal of Clinical Medicine, 2019, 8, 1461.	1.0	7
585	Hippocampal Damage During Mechanical Ventilation in Trendelenburg Position: A Secondary Analysis of an Experimental Study on the Prevention of Ventilator-Associated Pneumonia. Shock, 2019, 52, 75-82.	1.0	7
586	Soluble urokinase plasminogen activator receptor for the prediction of ventilator-associated pneumonia. ERJ Open Research, 2019, 5, 00212-2018.	1.1	7
587	Pseudomonas aeruginosa in Bronchiectasis. Seminars in Respiratory and Critical Care Medicine, 2021, 42, 587-594.	0.8	7
588	Entendimento da mortalidade em pneumonia pneumococica bacteriemia. Jornal Brasileiro De Pneumologia, 2012, 38, 419-421.	0.4	7
589	Ethics roundtable debate: A patient dies from an ICU-acquired infection related to methicillin-resistant Staphylococcus aureus—how do you defend your case and your team?. Critical Care, 2004, 9, 5.	2.5	6
590	MEK inhibition induces caspases activation, differentiation blockade and PML/RAR $\alpha$ degradation in acute promyelocytic leukaemia. British Journal of Haematology, 2008, 142, 27-35.	1.2	6
591	Salting-out procedure for isolation of DNA from stored bone marrow slides for PCR. European Journal of Haematology, 1993, 50, 237-238.	1.1	6
592	What Is an Interventional Pulmonology Unit in Europe?. Clinical Pulmonary Medicine, 2010, 17, 42-46.	0.3	6
593	Relation Between Chronic Obstructive Pulmonary Disease and Antibiotics. Current Infectious Disease Reports, 2012, 14, 300-307.	1.3	6
594	Corticosteroids for Severe Community-Acquired Pneumonia: Time to Change Clinical Practice. Annals of Internal Medicine, 2015, 163, 560-561.	2.0	6

#	ARTICLE	IF	CITATIONS
595	Bacterial Pneumonia and Lung Abscess. , 2016, , 557-582.e22.		6
596	Research in community-acquired pneumonia: the next steps. Intensive Care Medicine, 2017, 43, 1395-1397.	3.9	6
597	Diagnostic Value of Endotracheal Aspirates Sonication on Ventilator-Associated Pneumonia Microbiologic Diagnosis. Microorganisms, 2017, 5, 62.	1.6	6
598	Lateral position during severe mono-lateral pneumonia: an experimental study. Scientific Reports, 2020, 10, 19372.	1.6	6
599	Safety considerations of current drug treatment strategies for nosocomial pneumonia. Expert Opinion on Drug Safety, 2021, 20, 181-190.	1.0	6
600	Thrombocytosis during Stable State Predicts Mortality in Bronchiectasis. Annals of the American Thoracic Society, 2021, 18, 1316-1325.	1.5	6
601	Eventos cardiovasculares tempranos y tardÃos en pacientes ingresados por neumonÃa adquirida en la comunidad. Archivos De Bronconeumologia, 2020, 56, 551-558.	0.4	6
602	Defining Community-Acquired Pneumonia as a Public Health Threat: Arguments in Favor from Spanish Investigators. Medical Sciences (Basel, Switzerland), 2020, 8, 6.	1.3	6
603	Pattern of expression of CXCR4 and adhesion molecules by human CD34+ cells from different sources: role in homing efficiency in NOD/SCID mice. Haematologica, 2004, 89, 1037-45.	1.7	6
604	Proteomic profiling of lung diffusion impairment in the recovery stage of SARSâ€CoVâ€2â€ induced ARDS. Clinical and Translational Medicine, 2022, 12, e838.	1.7	6
605	Early Recognition of Low-Risk SARS-CoV-2 Pneumonia. Chest, 2022, 162, 768-781.	0.4	6
606	Relationship between ventilator-associated pneumonia and intramucosal gastric pH: A case-control study. Journal of Critical Care, 1996, 11, 122-128.	1.0	5
607	Antibiotic prophylaxis strategies in the prevention of ventilator-associated pneumonia. Expert Opinion on Pharmacotherapy, 2003, 4, 1345-1354.	0.9	5
608	Respiratory infections after lung cancer resection. Expert Review of Anti-Infective Therapy, 2006, 4, 717-720.	2.0	5
609	Development and validation of a high performance liquid chromatography method to determine linezolid concentrations in pig pulmonary tissue. Clinical Chemistry and Laboratory Medicine, 2010, 48, 391-8.	1.4	5
610	Improving Type 1 Diabetes After Treatment of Immune Thrombocytopenia With Rituximab: Killing Two Birds With One Stone. Diabetes Care, 2010, 33, e122-e122.	4.3	5
611	The Barcelona Declaration from the World Alliance against Antibiotic Resistance: engagement of intensivists. Critical Care, 2012, 16, 145.	2.5	5
612	A week seems to be weak: tailoring duration of antibiotic treatment in Gram-negative ventilator-associated pneumonia. Critical Care, 2012, 17, 106.	2.5	5

#	ARTICLE	IF	CITATIONS
613	Significance of sputum purulence to guide antibiotic therapy in exacerbations of COPD. <i>European Respiratory Journal</i> , 2013, 41, 248-249.	3.1	5
614	Pharmacotherapy for hospital-acquired pneumonia. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 775-786.	0.9	5
615	Year in review in <i>Intensive Care Medicine</i> 2014: I. Cardiac dysfunction and cardiac arrest, ultrasound, neurocritical care, ICU-acquired weakness, nutrition, acute kidney injury, and miscellaneous. <i>Intensive Care Medicine</i> , 2015, 41, 179-191.	3.9	5
616	The effects of direct hemoperfusion using a polymyxin B-immobilized column in a pig model of severe <i>Pseudomonas aeruginosa</i> pneumonia. <i>Annals of Intensive Care</i> , 2016, 6, 58.	2.2	5
617	Neces-SARI-ly?. <i>Intensive Care Medicine</i> , 2016, 42, 928-930.	3.9	5
618	Editorial Commentary: Distinguishing Postobstructive Lung Infection From Community-Acquired Pneumonia. <i>Clinical Infectious Diseases</i> , 2016, 62, 962-963.	2.9	5
619	What's new in severe community-acquired pneumonia? Corticosteroids as adjunctive treatment to antibiotics. <i>Intensive Care Medicine</i> , 2016, 42, 1276-1278.	3.9	5
620	Evaluation of severity score-guided approaches to macrolide use in community-acquired pneumonia. <i>European Respiratory Journal</i> , 2017, 50, 1602306.	3.1	5
621	Soluble P-Selectin in Acute Exacerbations and Stable Bronchiectasis in Adults. <i>Annals of the American Thoracic Society</i> , 2019, 16, 1587-1591.	1.5	5
622	Is One Sample Enough? $\beta$ -Lactam Target Attainment and Penetration into Epithelial Lining Fluid Based on Multiple Bronchoalveolar Lavage Sampling Time Points in a Swine Pneumonia Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	5
623	Difficult to treat microorganisms in patients aged over 80 years with community-acquired pneumonia: the prevalence of PES pathogens. <i>European Respiratory Journal</i> , 2020, 56, 2000773.	3.1	5
624	Age is a determinant of short-term mortality in patients hospitalized for an acute exacerbation of COPD. <i>Internal and Emergency Medicine</i> , 2021, 16, 401-408.	1.0	5
625	Community-acquired pneumonia: Changing paradigms about mortality. <i>Community Acquired Infection</i> , 2014, 1, 1.	0.1	5
626	Effects of Aminophylline on Regional Diaphragmatic Shortening after Thoracotomy in the Awake Lamb. <i>Anesthesiology</i> , 1992, 77, 93-100.	1.3	4
627	Maintenance of tracheal tube cuff pressure: where are the limits?. <i>Critical Care</i> , 2008, 12, 106.	2.5	4
628	Treatment of hospital-acquired pneumonia. <i>Lancet Infectious Diseases</i> , The, 2011, 11, 728.	4.6	4
629	Invasive Pneumococcal Disease Today. <i>Clinical Pulmonary Medicine</i> , 2012, 19, 191-198.	0.3	4
630	What is next in sepsis: current trials in sepsis. <i>Expert Review of Anti-Infective Therapy</i> , 2012, 10, 859-862.	2.0	4

#	ARTICLE	IF	CITATIONS
631	New developments in the diagnosis of VAP make bronchoalveolar lavage less useful: some considerations. <i>Intensive Care Medicine</i> , 2014, 40, 1778-1779.	3.9	4
632	Should ultrasound be included in the initial assessment of respiratory patients?. <i>Lancet Respiratory Medicine</i> , 2014, 2, 599-600.	5.2	4
633	Are preoperative oral care bundles needed to prevent postoperative pneumonia?. <i>Intensive Care Medicine</i> , 2014, 40, 109-110.	3.9	4
634	Evidence in the eye of the beholder: about probiotics and VAP prevention. <i>Intensive Care Medicine</i> , 2016, 42, 1182-1184.	3.9	4
635	Non-invasive ventilation in hypoxemic acute respiratory failure: is it still possible?. <i>Intensive Care Medicine</i> , 2017, 43, 243-245.	3.9	4
636	Achoo, achis, ATCHIN! Vaccine youâ€¦. <i>European Respiratory Journal</i> , 2018, 51, 1702558.	3.1	4
637	Treatment with long acting muscarinic antagonists stimulates serum levels of irisin in patients with COPD. <i>Pulmonary Pharmacology and Therapeutics</i> , 2018, 48, 111-116.	1.1	4
638	Appraisal of systemic inflammation and diagnostic markers in a porcine model of VAP: secondary analysis from a study on novel preventive strategies. <i>Intensive Care Medicine Experimental</i> , 2018, 6, 42.	0.9	4
639	ICU-acquired pneumonia. <i>Current Opinion in Critical Care</i> , 2018, 24, 323-324.	1.6	4
640	Optimal approaches to preventing severe community-acquired pneumonia. <i>Expert Review of Respiratory Medicine</i> , 2019, 13, 1005-1018.	1.0	4
641	Development of a model for anemia of inflammation that is relevant to critical care. <i>Intensive Care Medicine Experimental</i> , 2019, 7, 47.	0.9	4
642	Influenza management with new therapies. <i>Current Opinion in Pulmonary Medicine</i> , 2020, 26, 215-221.	1.2	4
643	Exacerbations and Changes in Physical Activity and Sedentary Behaviour in Patients with Bronchiectasis after 1 Year. <i>Journal of Clinical Medicine</i> , 2021, 10, 1190.	1.0	4
644	Predictive Performance of Risk Factors for Multidrug-Resistant Pathogens in Nosocomial Pneumonia. <i>Annals of the American Thoracic Society</i> , 2021, 18, 807-814.	1.5	4
645	Outcome of Patients With Interstitial Lung Diseases Requiring Mechanical Ventilation. <i>Clinical Pulmonary Medicine</i> , 2005, 12, 26-31.	0.3	3
646	Transbronchial Needle Aspiration in the Study of Mediastinal Lymph Nodes: Yield and Cost-Effectiveness. <i>Archivos De Bronconeumologia</i> , 2008, 44, 290-294.	0.4	3
647	Guideline Tyranny: A Response to the Article by Baum and Kaltsas. <i>Clinical Infectious Diseases</i> , 2008, 47, 1117-1118.	2.9	3
648	Meeting the old man's friend. <i>Thorax</i> , 2009, 64, 1016-1017.	2.7	3

#	ARTICLE	IF	CITATIONS
649	Reply to Charles et al.. Clinical Infectious Diseases, 2009, 48, 1796-1797.	2.9	3
650	microRNA Methylation Profile Has Prognosis Impact in Acute Lymphoblastic Leukemia Patients Undergoing Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2011, 17, 745-748.	2.0	3
651	Role of multidrug-resistant pathogens in health-care-associated pneumonia – Authors' reply. Lancet Infectious Diseases, The, 2011, 11, 12-13.	4.6	3
652	New Insights in Positioning Tracheally Intubated and Mechanically Ventilated Patients. Clinical Pulmonary Medicine, 2012, 19, 174-182.	0.3	3
653	Telavancin in the treatment of nosocomial pneumonia: review of the clinical evidence. Clinical Investigation, 2012, 2, 939-948.	0.0	3
654	Immunological Features and Clinical Benefits of Conjugate Vaccines against Bacteria. Journal of Immunology Research, 2015, 2015, 1-3.	0.9	3
655	Prone position and VAP incidence in the PROSEVA trial: attention to the causal question when interpreting competing risk analysis. Intensive Care Medicine, 2016, 42, 2119-2120.	3.9	3
656	Development of a device to reduce gastro-esophageal reflux in critically ill patients. Clinical Nutrition Experimental, 2016, 7, 1-8.	2.0	3
657	Noninvasive Ventilation with Helium/Oxygen in Chronic Obstructive Pulmonary Disease Exacerbations. When Physiologic Improvement Does Not Translate into Clinical Benefit. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 843-844.	2.5	3
658	Hospitalized acute exacerbations of chronic obstructive pulmonary disease: which patients may have a negative clinical outcome?. Expert Review of Respiratory Medicine, 2019, 13, 691-693.	1.0	3
659	An in-vitro study to evaluate high-volume low-pressure endotracheal tube cuff deflation dynamics. Minerva Anestesiologica, 2019, 85, 846-853.	0.6	3
660	Feasibility of computerized adventitious respiratory sounds to assess the effects of airway clearance techniques in patients with bronchiectasis. Physiotherapy Theory and Practice, 2020, 36, 1245-1255.	0.6	3
661	How may we improve clinical outcomes for patients hospitalized with acute exacerbations of chronic obstructive pulmonary disease? A narrative review about possible therapeutic and preventive strategies. Expert Review of Respiratory Medicine, 2020, 14, 493-500.	1.0	3
662	Strategies for implementation of a multidisciplinary approach to the treatment of nosocomial infections in critically ill patients. Expert Review of Anti-Infective Therapy, 2021, 19, 759-767.	2.0	3
663	Prediction of ventilator-associated pneumonia outcomes according to the early microbiological response: a retrospective observational study. European Respiratory Journal, 2022, 59, 2100620.	3.1	3
664	Too Much or Too Little Empiric Treatment for <i>Pseudomonas aeruginosa</i> in Community-acquired Pneumonia?. Annals of the American Thoracic Society, 2021, 18, 1456-1458.	1.5	3
665	Pyogenic Bacterial Pneumonia and Lung Abscess. , 2010, , 699-740.		3
666	A pooled analysis of patients with wound infections in the Phase 3 REVIVE trials: randomized, double-blind studies to evaluate the safety and efficacy of iclaprim versus vancomycin for treatment of acute bacterial skin and skin structure infections. Journal of Medical Microbiology, 2020, 69, 625-630.	0.7	3

#	ARTICLE	IF	CITATIONS
667	Pneumoperitoneum. <i>Critical Care Medicine</i> , 1985, 13, 138.	0.4	2
668	Nosocomial pneumonia. <i>Current Opinion in Infectious Diseases</i> , 1993, 6, 163-170.	1.3	2
669	Respiratory Infections After Lung Cancer Resection. <i>Clinical Pulmonary Medicine</i> , 2006, 13, 8-16.	0.3	2
670	Reply to Collins et al. and to Singh. <i>Clinical Infectious Diseases</i> , 2007, 45, 134-135.	2.9	2
671	Molecular immaturity of the immune receptor genes in a case of acute leukaemia with complete lymphoid lineage switch. <i>European Journal of Haematology</i> , 1995, 55, 61-62.	1.1	2
672	Role of Defective Thymic Function in Onset of Ganciclovir-Resistant Cytomegalovirus after Cord Blood Transplantation. <i>Vaccine Journal</i> , 2012, 19, 1994-1998.	3.2	2
673	Physiotherapy in Mechanically Ventilated Patients. <i>Clinical Pulmonary Medicine</i> , 2013, 20, 292-299.	0.3	2
674	Predicting Community-Acquired Pneumonia Etiology: Response. <i>Chest</i> , 2013, 144, 1976.	0.4	2
675	IgA level in plasma as a differential factor for influenza infection in severe viral pneumonia. <i>Journal of Clinical Virology</i> , 2014, 59, 135-136.	1.6	2
676	Respiratory infections management: Still a challenge. <i>Pulmonary Pharmacology and Therapeutics</i> , 2015, 32, 117-118.	1.1	2
677	Epidemiology, etiology, and risk factors of bacterial pneumonia. , 2015, , 7-28.		2
678	Pneumonia in 2016: towards better care. <i>Lancet Respiratory Medicine</i> , the, 2016, 4, 949-951.	5.2	2
679	The clinical management of lower respiratory tract infections. <i>Expert Review of Respiratory Medicine</i> , 2016, 10, 441-452.	1.0	2
680	Respiratory research networks in Europe and beyond: aims, achievements and aspirations for the 21st century. <i>Breathe</i> , 2017, 13, 209-215.	0.6	2
681	Rapid identification of antimicrobial resistance patterns allows a faster antibiotic adequacy. <i>Critical Care</i> , 2017, 21, 208.	2.5	2
682	Exacerbation of Bronchiectasis. , 2018, , 205-222.		2
683	New Insights into the Regulation of Endothelial Lung Permeability in Pneumonia. The Interplay between Angiopoietins 1 and 2. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 198, 149-150.	2.5	2
684	The effect of pulmonary surfactant on the in vitro activity of Iclaprim against common respiratory bacterial pathogens. <i>Diagnostic Microbiology and Infectious Disease</i> , 2018, 90, 64-66.	0.8	2

#	ARTICLE	IF	CITATIONS
685	Looking for Predictors of Early Readmission in Chronic Obstructive Pulmonary Disease: Every Effort Is Required. <i>Annals of the American Thoracic Society</i> , 2018, 15, 1366-1366.	1.5	2
686	Clinical Factors Associated with a Shorter or Longer Course of Antibiotic Treatment in Patients with Exacerbations of Bronchiectasis: A Prospective Cohort Study. <i>Journal of Clinical Medicine</i> , 2019, 8, 1950.	1.0	2
687	Severe Community-Acquired Pneumonia. , 2019, , .		2
688	The European Network for ICU-Related Respiratory Infections (ENIRRI) ERS Clinical Research Collaboration. <i>European Respiratory Journal</i> , 2019, 53, 1801972.	3.1	2
689	Aetiological diagnosis in new adult outpatients with bronchiectasis:role of predictors derived from real life experience. <i>Respiratory Medicine</i> , 2020, 172, 106090.	1.3	2
690	Noninvasive Ventilation and High-Flow Nasal Therapy Administration in Chronic Obstructive Pulmonary Disease Exacerbations. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2020, 41, 786-797.	0.8	2
691	Systemic Inflammatory Response and Outcomes in Community-Acquired Pneumonia Patients Categorized According to the Smoking Habit or Presence of Chronic Obstructive Pulmonary Disease. <i>Journal of Clinical Medicine</i> , 2020, 9, 2884.	1.0	2
692	Association between sepsis at ICU admission and mortality in patients with ICU-acquired pneumonia: An infectious second-hit model. <i>Journal of Critical Care</i> , 2020, 59, 207-214.	1.0	2
693	Are Macrolides as Effective as Fluoroquinolones in Legionella Pneumonia? Yes, butâ€¦. <i>Clinical Infectious Diseases</i> , 2021, 72, 1990-1991.	2.9	2
694	Shifting the paradigm: unilateral infiltrates and ARDS?. <i>European Respiratory Journal</i> , 2021, 57, 2100043.	3.1	2
695	Impact of Cardiovascular Failure in Intensive Care Unit-Acquired Pneumonia: A Single-Center, Prospective Study. <i>Antibiotics</i> , 2021, 10, 798.	1.5	2
696	Corticosteroids for severe CAP: the pros. <i>Revista Brasileira De Terapia Intensiva</i> , 2015, 27, 202-4.	0.1	2
697	Development and characterization of a new swine model of invasive pneumococcal pneumonia. <i>Lab Animal</i> , 2021, 50, 327-335.	0.2	2
698	<i>Pseudomonas Aeruginosa</i> and Initial Antibiotic Choices. <i>Perspectives on Critical Care Infectious Diseases</i> , 2001, , 105-118.	0.1	2
699	Perspectives of patients, family members, health professionals and the public on the impact of COVID-19 on mental health. <i>Journal of Mental Health</i> , 2022, 31, 524-533.	1.0	2
700	Comparison of the inflammatory response in ARDS and pneumonia: possible implication for the differential diagnosis. <i>Intensivmedizin Und Notfallmedizin</i> , 1999, 36, 702-708.	0.2	1
701	Colonization with <i>Pseudomonas aeruginosa</i> in critically ill patients and measures for its prevention. <i>Netherlands Journal of Medicine</i> , 1999, 55, 100-102.	0.6	1
702	Drug-Resistant <i>Streptococcus pneumoniae</i> : Impact on Diagnosis and Treatment of Community-Acquired Pneumonia. <i>Clinical Pulmonary Medicine</i> , 2001, 8, 318-326.	0.3	1



#	ARTICLE	IF	CITATIONS
703	Pneumoconiosis in Coal Workers: Cellular Concepts of Dust-Induced Lung Injury, Radiographic Diagnosis, and Pulmonary Infections With Mycobacteria. <i>Clinical Pulmonary Medicine</i> , 2001, 8, 13-21.	0.3	1
704	Noninvasive Ventilation During Weaning From Mechanical Ventilation. <i>Clinical Pulmonary Medicine</i> , 2002, 9, 279-283.	0.3	1
705	Community-Acquired Pneumonia: <i>Staphylococcus aureus</i> . , 2002, , 475-485.		1
706	Nonresponding Pneumonia. <i>Clinical Pulmonary Medicine</i> , 2004, 11, 298-306.	0.3	1
707	Current Perspectives on <i>Streptococcus pneumoniae</i> Antibiotic Resistance, With Particular Reference to Isolates From Spain. <i>Clinical Pulmonary Medicine</i> , 2005, 12, 210-219.	0.3	1
708	Pathophysiology of Pneumonia. , 0, , 63-78.		1
709	Genetic risk factors for acute respiratory distress syndrome: What's the right direction to take?*. <i>Critical Care Medicine</i> , 2007, 35, 293-294.	0.4	1
710	New Biological Markers of Ventilator-Associated Pneumonia. <i>Clinical Pulmonary Medicine</i> , 2007, 14, 93-98.	0.3	1
711	Risk Factors for Multidrug-Resistant Pneumococcal Pneumonia. <i>Infectious Diseases in Clinical Practice</i> , 2008, 16, 368-375.	0.1	1
712	Non-Responding Pneumonia. , 0, , 213-227.		1
713	Community-Acquired Pneumonia. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2009, 30, 125-126.	0.8	1
714	Reply to van Saene et al.. <i>Intensive Care Medicine</i> , 2009, 35, 1817-1817.	3.9	1
715	The Importance of <i>Aspergillus</i> species Infection in Chronic Obstructive Pulmonary Disease Exacerbations. <i>Clinical Pulmonary Medicine</i> , 2011, 18, 161-168.	0.3	1
716	Comment on "Pneumonia associated with invasive and noninvasive ventilation: an analysis of the German nosocomial infection surveillance system database". <i>Intensive Care Medicine</i> , 2011, 37, 1041-1042.	3.9	1
717	Influenza A (H1N1) Pneumonia. <i>Clinical Pulmonary Medicine</i> , 2012, 19, 246-253.	0.3	1
718	Diagnosis of ventilator-associated pneumonia. <i>Critical Care Medicine</i> , 2012, 40, 3311-3312.	0.4	1
719	DEVELOPMENT AND VALIDATION OF A HIGH PERFORMANCE LIQUID CHROMATOGRAPHY METHOD TO DETERMINE VANCOMYCIN CONCENTRATIONS IN PLASMA AND PIG PULMONARY TISSUE. <i>Journal of Liquid Chromatography and Related Technologies</i> , 2012, 35, 240-257.	0.5	1
720	Physiology of Urine Volume. , 2012, , 1732-1734.		1

#	ARTICLE	IF	CITATIONS
721	Expiratory Rib Cage Compressions to Improve Secretion Clearance During Mechanical Ventilation: Not Only a Matter of Squeezing the Chest. <i>Respiratory Care</i> , 2014, 59, e119-e120.	0.8	1
722	Author's response to "CAP and HCAP are different? An unresolved question". <i>Thorax</i> , 2014, 69, 677-678.	2.7	1
723	Importance of a registered and structured protocol when conducting systematic reviews: comments about nebulized antibiotics for ventilator-associated pneumonia. <i>Critical Care</i> , 2015, 19, 298.	2.5	1
724	Cardiovascular and Inflammatory Biomarkers for Defining the Prognosis of CAP. <i>Clinical Pulmonary Medicine</i> , 2015, 22, 114-122.	0.3	1
725	Systemic Antibiotics and Respiratory Tract Colonization in Critically Ill Patients. <i>Critical Care Medicine</i> , 2015, 43, 911-912.	0.4	1
726	Mortality of CAP reduced in the UK: is this enough?. <i>Thorax</i> , 2016, 71, 979-980.	2.7	1
727	The Importance of Phenotyping Bronchiectasis. <i>Respiration</i> , 2016, 92, 134-135.	1.2	1
728	Reflujo gastroesofágico en pacientes con ventilación mecánica: hacia el manejo integral mediante la analogía del «pozo de petrleo». <i>Acta Colombiana De Cuidado Intensivo</i> , 2017, 17, 184-194.	0.1	1
729	Has Mortality of Community-Acquired Pneumonia Really Reduced?. <i>Clinical Pulmonary Medicine</i> , 2017, 24, 258-262.	0.3	1
730	ERS syllabus for postgraduate training in respiratory infections: a guide for comprehensive training. <i>Breathe</i> , 2018, 14, 269-275.	0.6	1
731	Treating HIV-Positive/Non-AIDS Patients for Community-Acquired Pneumonia with ART. <i>Current Infectious Disease Reports</i> , 2018, 20, 46.	1.3	1
732	Community-acquired Pneumonia and Acute Respiratory Distress Syndrome: Prevalence, Risk, and Prognosis. <i>Clinical Pulmonary Medicine</i> , 2018, 25, 100-106.	0.3	1
733	Addendum: Cillniz, C.; Domined, C.; Nicolini, A.; Torres, A. PES Pathogens in Severe Community-Acquired Pneumonia. <i>Microorganisms</i> 2019, 7, 49. <i>Microorganisms</i> , 2019, 7, 168.	1.6	1
734	Perspectives on synthetic pharmacotherapy for the treatment of nosocomial pneumonia. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 1439-1448.	0.9	1
735	24th International Symposium on Infections in the Critically Ill Patient. <i>Medical Sciences (Basel)</i> , 2019, 8, 113-114. <i>Tj ETQq1 1 0.784314 rgBT /Overlock</i>	1.3	1
736	Economic analysis of ceftaroline fosamil for treating community-acquired pneumonia in Spain. <i>Journal of Medical Economics</i> , 2020, 23, 148-155.	1.0	1
737	Reply to Musher. <i>Journal of Infectious Diseases</i> , 2020, 222, 334-335.	1.9	1
738	Efficacy of Telavancin in Comparison to Linezolid in a Porcine Model of Severe Methicillin-Resistant <i>Staphylococcus aureus</i> Pneumonia. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 65, .	1.4	1

#	ARTICLE	IF	CITATIONS
739	Characteristics and Outcomes in Patients with Ventilator-Associated Pneumonia Who Do or Do Not Develop Acute Respiratory Distress Syndrome. An Observational Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 3508.	1.0	1
740	Ventilator-associated pneumonia. <i>Current Opinion in Infectious Diseases</i> , 2020, 33, 1.	1.3	1
741	The safety of antimicrobials for the treatment of community-acquired pneumonia. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 577-587.	1.0	1
742	Short-Term Effects of Appropriate Empirical Antimicrobial Treatment with Ceftolozane/Tazobactam in a Swine Model of Nosocomial Pneumonia. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	1.4	1
743	What's Next in Pneumonia?. <i>Archivos De Bronconeumologia</i> , 2022, 58, 208-210.	0.4	1
744	Epidemiology of Acute Respiratory Failure in Patients with HM (ICU Only). , 2011, , 47-55.		1
745	Nosocomial Pneumonia. , 2011, , 464-480.		1
746	Community-Acquired Pneumococcal Pneumonia in Virologically Suppressed HIV-Infected Adult Patients: A Matched Case-Control Study. , 2017, , .		1
747	LATE-BREAKING ABSTRACT: Differences in <i>S. pneumoniae</i> serotypes distribution causing CAP in hospitalized adults in Spain according to comorbidities by a new urinary antigen detection (UAD) test. The CAPA study. , 2015, , .		1
748	Community-acquired pneumonia due to multidrug and non-multidrug resistant <i>Pseudomonas aeruginosa</i> . , 2016, , .		1
749	Pathology and clinical features of pneumonia. , 2015, , 29-37.		1
750	Biomarkers in community-acquired pneumonia: can we do better by using them correctly?. <i>Jornal Brasileiro De Pneumologia</i> , 2019, 45, e20190189.	0.4	1
751	Impact on in-hospital mortality of ceftaroline versus standard of care in community-acquired pneumonia: a propensity-matched analysis. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2022, 41, 271-279.	1.3	1
752	Evaluation of Respiratory Sequelae in Patients With COVID-19, Where we are and Where we are Going. CIBERESUCICOVID and RECOVID Studies to Compare Patients Admitted to ICU vs Conventional Ward. <i>Archivos De Bronconeumologia</i> , 2022, 58, T115-T116.	0.4	1
753	Safety of Percutaneous Lung Needle Aspiration. <i>Chest</i> , 1991, 100, 1739.	0.4	0
754	Diagnosis of ventilator-associated pneumonia. <i>Current Opinion in Anaesthesiology</i> , 1996, 9, 157-161.	0.9	0
755	Histopathologic and Microbiologic Aspects of Ventilator-Associated Pneumonia. <i>Survey of Anesthesiology</i> , 1997, XLI, 82-83.	0.1	0
756	Pneumonia and Acute Lung Injury: New Insights on Histopathology. <i>Sepsis</i> , 1998, 1, 161-171.	0.5	0

#	ARTICLE	IF	CITATIONS
757	Gastric Intramucosal pH Monitoring in Weaning. <i>Clinical Pulmonary Medicine</i> , 2000, 7, 85-89.	0.3	0
758	Acute Respiratory Distress Syndrome and Pulmonary Infection. <i>Clinical Pulmonary Medicine</i> , 2002, 9, 253-259.	0.3	0
759	Reply to De Maria et al.. <i>Clinical Infectious Diseases</i> , 2005, 40, 1375-1376.	2.9	0
760	Intermediate Respiratory Care Units. <i>Clinical Pulmonary Medicine</i> , 2006, 13, 289-295.	0.3	0
761	Decrease in Drug Resistance in Pneumococcal Community-Acquired Pneumonia. <i>Chest</i> , 2007, 132, 359-360.	0.4	0
762	Continuous cuff pressure control and the prevention of ventilator-associated pneumonia. <i>Critical Care Medicine</i> , 2007, 35, 2471.	0.4	0
763	Community-Acquired Pneumonia in Alcoholic Patients. <i>Clinical Pulmonary Medicine</i> , 2007, 14, 258-264.	0.3	0
764	Advances in lower respiratory tract infections in critically ill patients. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2007, 25, 47-57.	0.3	0
765	Tratamiento antimicrobiano de la enfermedad pulmonar obstructiva crónica en el anciano. <i>Semergen</i> , 2007, 33, 65-79.	0.2	0
766	Update on infections in ICU patients. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2008, 26, 39-48.	0.3	0
767	Reply to Mohapatra et al.. <i>Clinical Infectious Diseases</i> , 2008, 47, 857-858.	2.9	0
768	Predicting Need for ICU in Community-Acquired Pneumonia. <i>Chest</i> , 2008, 133, 588.	0.4	0
769	Empirical Treatment of Community-Acquired Pneumonia: Current Guidelines. , 0, , 63-100.		0
770	β-Lactams in the Therapy of Community-Acquired Pneumonia. , 0, , 153-169.		0
771	Macrolides and Ketolides. , 0, , 171-191.		0
772	Pulmonary Infiltrates in HIV Patients in the Highly Active Antiretroviral Therapy Era. <i>Clinical Pulmonary Medicine</i> , 2008, 15, 313-324.	0.3	0
773	Role of Fluoroquinolones in the Treatment of Community-Acquired Pneumonia. , 0, , 193-212.		0
774	Epidemiology of Adult Hospitalized Community-Acquired Pneumonia. , 0, , 5-19.		0

#	ARTICLE	IF	CITATIONS
775	Pathogen Directed Antimicrobial Treatment of Pneumonia. , 0, , 101-126.		0
776	Adjunctive Therapy in Community-Acquired Pneumonia. , 0, , 245-262.		0
777	Microbiological Diagnosis of Community-Acquired Pneumonia. , 0, , 43-61.		0
778	Microbial Aetiology and Antibiotic Resistances in Community-Acquired Pneumonia. , 0, , 21-41.		0
779	Inhaled Steroids and Risk of Community-Acquired Pneumonia. Clinical Pulmonary Medicine, 2009, 16, 127-131.	0.3	0
780	A Clinical Pathway for Diagnosing and Staging Lung Cancer. Clinical Pulmonary Medicine, 2009, 16, 150-156.	0.3	0
781	Reply to Kollef. Clinical Infectious Diseases, 2010, 50, 618-620.	2.9	0
782	Systemic Inflammatory Response as a Risk and Prognosis Factor in Ventilator-Associated Pneumonia. Current Respiratory Medicine Reviews, 2010, 6, 11-14.	0.1	0
783	Withdrawal of Noninvasive Mechanical Ventilation in COPD Patients with Hypercapnic Respiratory Failure. , 2010, , 179-184.		0
784	Severe, non-bacteremic infections in ICU patients. Enfermedades Infecciosas Y Microbiología Clínica, 2011, 29, 1-9.	0.3	0
785	Should the ATS/IDSA Guidelines for Hospital-acquired and Ventilator-associated Pneumonia be Reevaluated?. Clinical Pulmonary Medicine, 2011, 18, 8-13.	0.3	0
786	Endobronchial Ultrasound Today. Clinical Pulmonary Medicine, 2011, 18, 34-38.	0.3	0
787	Biomarkers and Pneumonia: Should We All be Using Them?. Current Respiratory Medicine Reviews, 2011, 7, 262-267.	0.1	0
788	Antibiotics Before Hospitalization for CAP. Clinical Pulmonary Medicine, 2012, 19, 109-112.	0.3	0
789	Nosocomial Respiratory Infections. , 2012, , 322-329.		0
790	PRAM (Pressure Recording Analytical Method). , 2012, , 1803-1803.		0
791	Pulse-temperature Dissociation. , 2012, , 1934-1934.		0
792	The authors reply. Critical Care Medicine, 2013, 41, e135-e136.	0.4	0

#	ARTICLE	IF	CITATIONS
793	Assisted Ventilation. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2014, 35, 407-408.	0.8	0
794	HCAP. <i>Clinical Pulmonary Medicine</i> , 2014, 21, 113-119.	0.3	0
795	Corticosteroids in the Critically Ill Patient. <i>Clinical Pulmonary Medicine</i> , 2015, 22, 215-222.	0.3	0
796	The PES (Pseudomonas, Enterobacteriaceae ESBL, Methicillin-resistant Staphylococcus aureus) Concept in Community-acquired Pneumonia. <i>Clinical Pulmonary Medicine</i> , 2015, 22, 265-270.	0.3	0
797	Treatment for Hospitalized Patients With Severe Community-Acquired Pneumonia—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 2184.	3.8	0
798	Reducing antibiotics use for ventilator-associated pneumonia in brain-injured patients. <i>European Respiratory Journal</i> , 2016, 47, 1060-1061.	3.1	0
799	Response. <i>Chest</i> , 2016, 150, 757.	0.4	0
800	Community acquired pneumonia in asthma: Not a threatening combination. <i>Respiratory Medicine</i> , 2016, 112, 136.	1.3	0
801	Risk factors for community-acquired pneumonia in adults. <i>Minerva Respiratory Medicine</i> , 2017, 56, .	0.1	0
802	Multidrug-resistant pathogens in respiratory diseases. <i>Minerva Respiratory Medicine</i> , 2017, 56, .	0.1	0
803	COPD 2017: A Year in Review. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2018, 15, 118-122.	0.7	0
804	Reply to Akinosoglou and Gogos: Sepsis-3 in Community-acquired Pneumonia: How Reliable Is It?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 197, 537-538.	2.5	0
805	Response. <i>Chest</i> , 2019, 156, 415.	0.4	0
806	Impact of Cefotaxime Non-susceptibility on the Clinical Outcomes of Bacteremic Pneumococcal Pneumonia. <i>Journal of Clinical Medicine</i> , 2019, 8, 1150.	1.0	0
807	Letter from Spain. <i>Respirology</i> , 2019, 24, 817-818.	1.3	0
808	Reply to Head and Keynan. <i>Clinical Infectious Diseases</i> , 2019, 68, 1433-1434.	2.9	0
809	The War against Bad Bugs: Fighting the Resistance. <i>Journal of Clinical Medicine</i> , 2020, 9, 2563.	1.0	0
810	COPD in the Intensive Care Unit. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2020, 41, 785-785.	0.8	0

#	ARTICLE	IF	CITATIONS
811	Reply to "Dual antibiotic therapy for outpatient management of community-acquired pneumonia". Archivos De Bronconeumologia, 2020, 56, 766-767.	0.4	0
812	Respuesta a "Dual antibiotic therapy for outpatient management of community-acquired pneumonia". Archivos De Bronconeumologia, 2020, 56, 766-767.	0.4	0
813	Outcomes of Critically Ill Very Old Patients With Community-Acquired Pneumonia and Acute Respiratory Distress Syndrome. Archivos De Bronconeumologia, 2021, , .	0.4	0
814	Hospital-Acquired and Ventilator-Associated Pneumonia. , 2022, , 206-219.		0
815	Cardiovascular Events during and after Bronchiectasis Exacerbations and Long-Term Mortality. Chest, 2021, , .	0.4	0
816	Ventilator-Associated Pneumonia: Is Prevention Cost-Effective?. Perspectives on Critical Care Infectious Diseases, 2001, , 155-167.	0.1	0
817	Role of Invasive Devices in the Pathogenesis of Nosocomial Pneumonia. , 2001, , 127-136.		0
818	Ventilator-Associated Pneumonia. , 2006, , 175-186.		0
819	Diagnostic approach in ventilator-associated pneumonia. , 2006, , 629-639.		0
820	Epidemiology of nosocomial respiratory infections. , 2006, , 585-594.		0
821	Nosocomial Pneumonia. , 2008, , 379-384.		0
822	Ventilator-Associated Pneumonia. , 2008, , 645-649.		0
823	Corticoids in Severe Pneumonia. , 2008, , 45-51.		0
824	Prevention of VAP: role of the artificial airway, body position and setting the ventilator. , 2012, , 153-168.		0
825	Dealing with infection after thoracic surgical procedures. , 2013, , 171-180.		0
826	CAP phenotypes. , 2014, , 105-116.		0
827	Intriguing on First Sight. Critical Care Medicine, 1999, 27, 2600-2601.	0.4	0
828	Introduction to pneumonia. , 2015, , 1-5.		0

#	ARTICLE	IF	CITATIONS
829	Management of pneumonia. , 2015, , 75-98.		0
830	Methods for preventing pneumonia. , 2015, , 57-73.		0
831	Diagnosis and classification of Pneumonia. , 2015, , 39-56.		0
832	Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: A randomized clinical trial. , 2015, , .		0
833	Personalizing pneumococcal vaccination recommendations: The Saudi Thoracic Society guidelines. Annals of Thoracic Medicine, 2016, 11, 89.	0.7	0
834	Macrolide combination therapy for hospitalised CAP patients? An individualised approach supported by machine learning. European Respiratory Journal, 2019, 54, 1902111.	3.1	0
835	Severe community-acquired pneumonia. , 0, , 101-116.		0
836	Defining Clinical and Microbiological Nonresponse in Ventilator-Associated Pneumonia. Seminars in Respiratory and Critical Care Medicine, 2022, , .	0.8	0
837	Diagn�stico de la neumon�a: una necesidad compartida. Enfermedades Infecciosas Y Microbiolog�a Cl�nica, 2023, 41, 57-58.	0.3	0